BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, Klump B, Budach W, Teichmann R, Schmitt M. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23:2310-2317. [PMID: 15800321 DOI: 10.1200/jco.2005.00.034] [Cited by in Crossref: 869] [Cited by in F6Publishing: 786] [Article Influence: 51.1] [Reference Citation Analysis]
Number Citing Articles
1 Ren G, Wang Z, Tian Y, Li J, Ma Y, Zhou L, Zhang C, Guo L, Diao H, Li L, Lu L, Ma S, Wu Z, Yan L, Liu W. Targeted chemo-photodynamic therapy toward esophageal cancer by GSH-sensitive theranostic nanoplatform. Biomedicine & Pharmacotherapy 2022;153:113506. [DOI: 10.1016/j.biopha.2022.113506] [Reference Citation Analysis]
2 Zhang T, Guo Z, Chen X, Dong J, Jiang H, Tang P, Wang P, Qian D, Zhang W, Pang Q. A retrospective study comparing definitive chemoradiotherapy vs. chemoradiotherapy followed by surgery in T4 esophageal squamous cell carcinoma patients who were downstaged after neochemoradiotherapy. Radiat Oncol 2022;17:148. [PMID: 35999608 DOI: 10.1186/s13014-022-02116-0] [Reference Citation Analysis]
3 De Bari B, Lefevre L, Henriques J, Gatta R, Falcoz A, Mathieu P, Borg C, Dinapoli N, Boulahdour H, Boldrini L, Valentini V, Vernerey D. Could 18-FDG PET-CT Radiomic Features Predict the Locoregional Progression-Free Survival in Inoperable or Unresectable Oesophageal Cancer? Cancers (Basel) 2022;14:4043. [PMID: 36011035 DOI: 10.3390/cancers14164043] [Reference Citation Analysis]
4 Boustani J, Créhange G. [Dose-escalated radiotherapy in esophageal cancer: A review of the literature]. Cancer Radiother 2022:S1278-3218(22)00127-5. [PMID: 36008261 DOI: 10.1016/j.canrad.2022.06.021] [Reference Citation Analysis]
5 Solidum JGN, Rojo RD, Wo JY, Dee EC. Proton Beam Therapy for Esophageal Cancer. Cancers (Basel) 2022;14:4045. [PMID: 36011037 DOI: 10.3390/cancers14164045] [Reference Citation Analysis]
6 Lin CY, Lien MY, Chen CC, Fang HY, Lin YS, Chen CK, Chen JX, Lu TY, Huang TM, Hsieh TC, Sun SS, Li CC, Chien CR. Consolidative chemotherapy after definitive concurrent chemoradiotherapy for esophageal squamous cell carcinoma patients: a population based cohort study. BMC Gastroenterol 2022;22:381. [PMID: 35948871 DOI: 10.1186/s12876-022-02464-x] [Reference Citation Analysis]
7 Sakin A, Ozcelik M, Sahin S, Aydemir O, Aldemir MN, Iliklerden UH, Kotan MC. The prognostic effect of pretreatment 18F-FDG PET/CT metabolic parameters in locally advanced Esophageal Squamous Cell Carcinoma treated with definitive chemoradiotherapy. Surgical Oncology 2022;43:101809. [DOI: 10.1016/j.suronc.2022.101809] [Reference Citation Analysis]
8 Jensen GL, Hammonds KP, Haque W. Neoadjuvant versus definitive chemoradiation in locally advanced esophageal cancer for patients of advanced age or significant comorbidities. Dis Esophagus 2022:doac050. [PMID: 35901451 DOI: 10.1093/dote/doac050] [Reference Citation Analysis]
9 Ran JJ, Shen JJ, Ma J, Li XY. Survival analysis of 80 elderly patients with esophageal squamous cell carcinoma receiving definitive concurrent chemoradiotherapy with S-1. Cancer Radiother 2022:S1278-3218(22)00095-6. [PMID: 35864071 DOI: 10.1016/j.canrad.2022.04.007] [Reference Citation Analysis]
10 Liu J, Li Y, Chen Y, Jiang X, Yu H, Yan S, Hashmi MF. Long-Term Treatment Outcomes of the Elder Patients with Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma with Definitive Chemoradiotherapy or Radiotherapy. Contrast Media & Molecular Imaging 2022;2022:1-6. [DOI: 10.1155/2022/3678441] [Reference Citation Analysis]
11 Nilsson M, Olafsdottir H, Alexandersson von Döbeln G, Villegas F, Gagliardi G, Hellström M, Wang Q, Johansson H, Gebski V, Hedberg J, Klevebro F, Markar S, Smyth E, Lagergren P, Al-haidari G, Rekstad LC, Aahlin EK, Wallner B, Edholm D, Johansson J, Szabo E, Reynolds JV, Pramesh C, Mummudi N, Joshi A, Ferri L, Wong RK, O’callaghan C, Lukovic J, Chan KK, Leong T, Barbour A, Smithers M, Li Y, Kang X, Kong F, Chao Y, Crosby T, Bruns C, van Laarhoven H, van Berge Henegouwen M, van Hillegersberg R, Rosati R, Piessen G, de Manzoni G, Lordick F. Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed: The Study Protocol for the Randomized Controlled NEEDS Trial. Front Oncol 2022;12:917961. [DOI: 10.3389/fonc.2022.917961] [Reference Citation Analysis]
12 Obermannová R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M, van Grieken N, Vogel A, Smyth E. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology 2022. [DOI: 10.1016/j.annonc.2022.07.003] [Reference Citation Analysis]
13 Govindaraj K, Shanmugam S, Sampathrajan S. A feasibility and pilot study of the clinical efficacy of a custom designed handgrip device to improve patient immobilisation for the external beam radiotherapy of oesophageal cancers. Radiation Effects and Defects in Solids. [DOI: 10.1080/10420150.2022.2089141] [Reference Citation Analysis]
14 Jayaprakasam VS, Gibbs P, Gangai N, Bajwa R, Sosa RE, Yeh R, Greally M, Ku GY, Gollub MJ, Paroder V. Can 18F-FDG PET/CT Radiomics Features Predict Clinical Outcomes in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma? Cancers (Basel) 2022;14:3035. [PMID: 35740700 DOI: 10.3390/cancers14123035] [Reference Citation Analysis]
15 Ting YC, Hsu PK, Chen HS, Lin CH, Chuang CY, Hsu HS, Hsu CP. Surgery or Surveillance for Esophageal Squamous Cell Carcinoma With Clinical Complete Response After Neoadjuvant Chemoradiotherapy. Semin Thorac Cardiovasc Surg 2022:S1043-0679(22)00074-0. [PMID: 35691769 DOI: 10.1053/j.semtcvs.2022.04.003] [Reference Citation Analysis]
16 Li J, Chen B, Wang X, Xu C, Chen D, Zhu K, Jin Z, Qiu H, Shen J, Ye M. Prognosis of patients with esophageal squamous cell carcinoma undergoing surgery versus no surgery after neoadjuvant chemoradiotherapy: a retrospective cohort study. J Gastrointest Oncol 2022;13:903-11. [PMID: 35837186 DOI: 10.21037/jgo-22-296] [Reference Citation Analysis]
17 Ha LN, Chau ND, Bieu BQ, Son MH. Pretreatment 18F-FDG PET/CT-Derived Parameters in Predicting Clinical Outcomes of Locally Advanced Upper Third Esophageal Squamous Cell Carcinoma After Definitive Chemoradiation Therapy. Nucl Med Mol Imaging. [DOI: 10.1007/s13139-022-00751-9] [Reference Citation Analysis]
18 Yang YX, Zheng YZ, Gao TT, Liu SL, Xi M, Liu MZ, Wang JY, Qi SN, Yang Y, Zhao L. Progression-free survival at 3 years is a reliable surrogate for 5-year overall survival for patients suffering from locally advanced esophageal squamous cell carcinoma. Cancer Med 2022. [PMID: 35434962 DOI: 10.1002/cam4.4751] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Schiffner C, Christiansen H, Brandes I, Grannas G, Wichmann J, Merten R. Neoadjuvant versus definitive radiochemotherapy of locoregionally advanced oesophageal cancer-who benefits? Strahlenther Onkol 2022. [PMID: 35416495 DOI: 10.1007/s00066-022-01929-y] [Reference Citation Analysis]
20 Fernández-Montes A, Alcaide J, Alsina M, Custodio AB, Franco LF, Gallego Plazas J, Gómez-Martín C, Richart P, Rivera F, Martin-Richard M. SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021). Clin Transl Oncol 2022;24:658-69. [PMID: 35347573 DOI: 10.1007/s12094-022-02801-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 van Holstein Y, Trompet S, van Deudekom FJ, van Munster B, de Glas NA, van den Bos F, Uit den Boogaard A, van der Elst MJT, van der Kaaij MAE, Neelis KJ, Langers AMJ, Slingerland M, Portielje JEA, Mooijaart SP. Geriatric assessment and treatment outcomes in a Dutch cohort of older patients with potentially curable esophageal cancer. Acta Oncol 2022;61:459-67. [PMID: 35193449 DOI: 10.1080/0284186X.2022.2036366] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Zhang-velten E, Sanford NN. The Evolving Role of Hypofractionated Radiotherapy in Older Adults with Gastrointestinal Cancers. Seminars in Radiation Oncology 2022;32:159-67. [DOI: 10.1016/j.semradonc.2021.11.005] [Reference Citation Analysis]
23 Waters JK, Reznik SI. Update on Management of Squamous Cell Esophageal Cancer. Curr Oncol Rep 2022. [PMID: 35142974 DOI: 10.1007/s11912-021-01153-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
24 Zhu J, Tao J, Dai Z, Tan Y, Jiang L, Wang Q, Lang J. Progression-Free Survival as Early Efficacy Endpoint in Resectable Esophageal Cancer Treated With Neoadjuvant Therapy: A Systematic Review. Front Oncol 2021;11:771546. [PMID: 35111667 DOI: 10.3389/fonc.2021.771546] [Reference Citation Analysis]
25 Subramanian MP, Puri V. Commentary: Getting on board with Bayesian analyses. The Journal of Thoracic and Cardiovascular Surgery 2022. [DOI: 10.1016/j.jtcvs.2022.02.011] [Reference Citation Analysis]
26 Zhu J, Tan Y, Wang Q. Letter to the editor regarding the article ‘‘Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy and esophagectomy for the treatment of esophageal and gastroesophageal carcinoma - A systematic review and meta-analysis” by Chow et al. Radiotherapy and Oncology 2022. [DOI: 10.1016/j.radonc.2022.01.041] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Cellini F, Manfrida S, Casà C, Romano A, Arcelli A, Zamagni A, De Luca V, Colloca GF, D'Aviero A, Fuccio L, Lancellotta V, Tagliaferri L, Boldrini L, Mattiucci GC, Gambacorta MA, Morganti AG, Valentini V. Modern Management of Esophageal Cancer: Radio-Oncology in Neoadjuvancy, Adjuvancy and Palliation. Cancers (Basel) 2022;14:431. [PMID: 35053594 DOI: 10.3390/cancers14020431] [Reference Citation Analysis]
28 Joseph DM, Malik MI, Jonnadula J, Ahmed F, Valiyaveettil D. Chemoradiation with Weekly Paclitaxel and Carboplatin in Esophageal Squamous Cell Carcinoma: A Prospective Study. South Asian J Cancer 2021;10:151-4. [PMID: 34938676 DOI: 10.1055/s-0041-1727067] [Reference Citation Analysis]
29 Li Y, Du Q, Wei X, Guo Z, Lei T, Li Y, Han D, Wu X, Zhang K, Zhang T, Chen X, Dong J, Zhang B, Wei H, Zhang W, Pang Q, Wang P. A Clinical Scoring Model to Predict the Effect of Induction Chemotherapy With Definitive Concurrent Chemoradiotherapy on Esophageal Squamous Cell Carcinoma Prognosis. Front Oncol 2021;11:703074. [PMID: 34912702 DOI: 10.3389/fonc.2021.703074] [Reference Citation Analysis]
30 Zhou N, Lee KH, Pedroza C, Hofstetter WL. Bayesian post-hoc analysis of chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Thorac Cardiovasc Surg 2021:S0022-5223(21)01681-0. [PMID: 34933771 DOI: 10.1016/j.jtcvs.2021.11.056] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Favareto SL, Sousa CF, Pinto PJ, Ramos H, Chen MJ, Castro DG, Silva ML, Gondim G, Pellizzon ACA, Fogaroli RC. Clinical Prognostic Factors for Patients With Esophageal Cancer Treated With Definitive Chemoradiotherapy. Cureus 2021;13:e18894. [PMID: 34820218 DOI: 10.7759/cureus.18894] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Matsuda S, Kawakubo H, Tsuji T, Aoyama J, Hirata Y, Takemura R, Mayanagi S, Irino T, Fukuda K, Nakamura R, Takeuchi H, Kitagawa Y. Clinical Significance of Endoscopic Response Evaluation to Predict the Distribution of Residual Tumor after Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. Ann Surg Oncol 2021. [PMID: 34812985 DOI: 10.1245/s10434-021-11009-7] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
33 Park J, Yea JW, Oh SA, Park JW. Omitting surgery in esophageal cancer patients with complete response after neoadjuvant chemoradiotherapy: a systematic review and meta-analysis. Radiat Oncol 2021;16:219. [PMID: 34775988 DOI: 10.1186/s13014-021-01947-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Chow R, Murdy K, Vaska M, Lee SL. Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy and esophagectomy for the treatment of esophageal and gastroesophageal carcinoma - A systematic review and meta-analysis. Radiother Oncol 2021;165:37-43. [PMID: 34695519 DOI: 10.1016/j.radonc.2021.10.013] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
35 Bolger JC, Donohoe CL, Lowery M, Reynolds JV. Advances in the curative management of oesophageal cancer. Br J Cancer 2021. [PMID: 34675397 DOI: 10.1038/s41416-021-01485-9] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
36 Hou S, Pan Z, Hao X, Hang Q, Ding Y. Recent Progress in the Neoadjuvant Treatment Strategy for Locally Advanced Esophageal Cancer. Cancers (Basel) 2021;13:5162. [PMID: 34680311 DOI: 10.3390/cancers13205162] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
37 Sun D, Chen Q, Gai Z, Zhang F, Yang X, Hu W, Chen C, Yang G, Hörmann S, Kullak-Ublick GA, Visentin M. The Role of the Carnitine/Organic Cation Transporter Novel 2 in the Clinical Outcome of Patients With Locally Advanced Esophageal Carcinoma Treated With Oxaliplatin. Front Pharmacol 2021;12:684545. [PMID: 34603016 DOI: 10.3389/fphar.2021.684545] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Hipp J, Thomaschewski M, Hummel R, Hoeppner J. [Complete response after neoadjuvant therapy for esophageal cancer : Implications for surgery]. Chirurg 2021. [PMID: 34596707 DOI: 10.1007/s00104-021-01509-3] [Reference Citation Analysis]
39 Hoefnagel SJM, Boonstra JJ, Russchen MJAM, Krishnadath KK. Towards Personalized Treatment Strategies for Esophageal Adenocarcinoma; A Review on the Molecular Characterization of Esophageal Adenocarcinoma and Current Research Efforts on Individualized Curative Treatment Regimens. Cancers (Basel) 2021;13:4881. [PMID: 34638363 DOI: 10.3390/cancers13194881] [Reference Citation Analysis]
40 van Kooten RT, Voeten DM, Steyerberg EW, Hartgrink HH, van Berge Henegouwen MI, van Hillegersberg R, Tollenaar RAEM, Wouters MWJM. Patient-Related Prognostic Factors for Anastomotic Leakage, Major Complications, and Short-Term Mortality Following Esophagectomy for Cancer: A Systematic Review and Meta-Analyses. Ann Surg Oncol 2021. [PMID: 34482453 DOI: 10.1245/s10434-021-10734-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
41 Choi Y, Choi JY, Hong TH, Choi YL, Oh D, Woo SY, Shim YM, Zo JI, Kim HK, Lee KS. Trimodality therapy for locally advanced esophageal squamous cell carcinoma: the role of volume-based PET/CT in patient management and prognostication. Eur J Nucl Med Mol Imaging 2021. [PMID: 34365522 DOI: 10.1007/s00259-021-05487-w] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
42 Wujanto C, Tey J, Vellayappan B, So J, Yong WP, Shabbir A, Tseng M, Soon YY, Ho F. Outcomes of oesophageal cancer treated with neoadjuvant compared with definitive chemoradiotherapy. Ann Acad Med Singap 2021;50:536-47. [DOI: 10.47102/annals-acadmedsg.2020633] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Duarte MBO, Pereira EB, Lopes LR, Andreollo NA, Carvalheira JBC. Chemoradiotherapy With or Without Surgery for Esophageal Squamous Cancer According to Hospital Volume. JCO Glob Oncol 2020;6:828-36. [PMID: 32552112 DOI: 10.1200/JGO.19.00360] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
44 Lapa C, Nestle U, Albert NL, Baues C, Beer A, Buck A, Budach V, Bütof R, Combs SE, Derlin T, Eiber M, Fendler WP, Furth C, Gani C, Gkika E, Grosu AL, Henkenberens C, Ilhan H, Löck S, Marnitz-Schulze S, Miederer M, Mix M, Nicolay NH, Niyazi M, Pöttgen C, Rödel CM, Schatka I, Schwarzenboeck SM, Todica AS, Weber W, Wegen S, Wiegel T, Zamboglou C, Zips D, Zöphel K, Zschaeck S, Thorwarth D, Troost EGC; Arbeitsgemeinschaft Nuklearmedizin und Strahlentherapie der DEGRO und DGN. Value of PET imaging for radiation therapy. Strahlenther Onkol 2021;197:1-23. [PMID: 34259912 DOI: 10.1007/s00066-021-01812-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
45 Lapa C, Nestle U, Albert NL, Baues C, Beer A, Buck A, Budach V, Bütof R, Combs SE, Derlin T, Eiber M, Fendler WP, Furth C, Gani C, Gkika E, Grosu AL, Henkenberens C, Ilhan H, Löck S, Marnitz-Schulze S, Miederer M, Mix M, Nicolay NH, Niyazi M, Pöttgen C, Rödel CM, Schatka I, Schwarzenboeck SM, Todica AS, Weber W, Wegen S, Wiegel T, Zamboglou C, Zips D, Zöphel K, Zschaeck S, Thorwarth D, Troost EGC; “Arbeitsgemeinschaft Nuklearmedizin und Strahlentherapie der DEGRO und DGN”. Value of PET imaging for radiation therapy. Nuklearmedizin 2021. [PMID: 34261141 DOI: 10.1055/a-1525-7029] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
46 Vlacich G, Ballard A, Badiyan SN, Spraker M, Henke L, Kim H, Lockhart AC, Park H, Suresh R, Huang Y, Robinson CG, Bradley JD, Samson PP. A single-institution phase I feasibility study of dose-escalated IMRT for non-operative locally advanced esophageal carcinoma. Clin Transl Radiat Oncol 2021;30:19-25. [PMID: 34278011 DOI: 10.1016/j.ctro.2021.06.007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
47 Yu Y, Zheng H, Liu L, Li H, Zheng Q, Wang Z, Wu Y, Li J. Predicting Severe Radiation Esophagitis in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Definitive Chemoradiotherapy: Construction and Validation of a Model Based in the Clinical and Dosimetric Parameters as Well as Inflammatory Indexes. Front Oncol 2021;11:687035. [PMID: 34249736 DOI: 10.3389/fonc.2021.687035] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
48 Li SH, Chen YH, Lu HI, Lo CM, Huang CC, Wang YM, Huang EY. Galectin-1 Expression Is Associated with the Response and Survival Following Preoperative Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma. Cancers (Basel) 2021;13:3147. [PMID: 34201887 DOI: 10.3390/cancers13133147] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
49 Oesophago-Gastric Anastomosis Study Group on behalf of the West Midlands Research Collaborative. Comparison of short-term outcomes from the International Oesophago-Gastric Anastomosis Audit (OGAA), the Esophagectomy Complications Consensus Group (ECCG), and the Dutch Upper Gastrointestinal Cancer Audit (DUCA). BJS Open 2021;5:zrab010. [PMID: 34021328 DOI: 10.1093/bjsopen/zrab010] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Thakur B, Devkota M, Chaudhary M. Management of Locally Advanced Esophageal Cancer. JNMA J Nepal Med Assoc 2021;59:409-16. [PMID: 34508544 DOI: 10.31729/jnma.4299] [Reference Citation Analysis]
51 Anap YS, Tanawade PK, Mathankar MJ, Mane-Patil AD, Bagul KG, Pawar RS, Pawar SB. Preoperative Chemoradiation in Locally-Advanced Resectable Carcinoma of the Esophagus in a Single Rural Cancer Hospital in Western India. South Asian J Cancer 2020;9:158-62. [PMID: 33937138 DOI: 10.1055/s-0041-1723075] [Reference Citation Analysis]
52 Li CC, Chen CY, Chou YH, Huang CJ, Ku HY, Chien CR. Chemotherapy alone versus definitive concurrent chemoradiotherapy for cT4b esophageal squamous cell carcinoma: a population-based study. BMC Gastroenterol 2021;21:153. [PMID: 33827451 DOI: 10.1186/s12876-021-01742-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
53 Lo CM, Wang YM, Chen YH, Fang FM, Huang SC, Lu HI, Li SH. The Impact of Radiotherapy Dose in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Preoperative Chemoradiotherapy. Curr Oncol 2021;28:1354-65. [PMID: 33805318 DOI: 10.3390/curroncol28020129] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
54 Pöttgen C, Gkika E, Stahl M, Abu Jawad J, Gauler T, Kasper S, Trarbach T, Herrmann K, Lehmann N, Jöckel KH, Lax H, Stuschke M. Dose-escalated radiotherapy with PET/CT based treatment planning in combination with induction and concurrent chemotherapy in locally advanced (uT3/T4) squamous cell cancer of the esophagus: mature results of a phase I/II trial. Radiat Oncol 2021;16:59. [PMID: 33757534 DOI: 10.1186/s13014-021-01788-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
55 Solomon D, Abbas M, Feferman Y, Haddad R, Perl G, Kundel Y, Morgenstern S, Menasherov N, Kashtan H. Signet Ring Cell Features are Associated with Poor Response to Neoadjuvant Treatment and Dismal Survival in Patients with High-Grade Esophageal Adenocarcinoma. Ann Surg Oncol 2021;28:4929-40. [PMID: 33709175 DOI: 10.1245/s10434-021-09644-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
56 Kastelowitz N, Marsh MD, McCarter M, Meguid RA, Bhardwaj NW, Mitchell JD, Weyant MJ, Scott C, Schefter T, Stumpf P, Leong S, Messersmith W, Lieu C, Leal AD, Davis SL, Purcell WT, Kane M, Wani S, Shah R, Hammad H, Edmundowicz S, Goodman KA. Impact of Radiation Dose on Postoperative Complications in Esophageal and Gastroesophageal Junction Cancers. Front Oncol 2021;11:614640. [PMID: 33777751 DOI: 10.3389/fonc.2021.614640] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
57 Rocha-Filho DR, Peixoto RD, Weschenfelder RF, Rego JFM, Riechelmann R, Coutinho AK, Fernandes GS, Jacome AA, Andrade AC, Murad AM, Mello CAL, Miguel DSCG, Gomes DBD, Racy DJ, Moraes ED, Akaishi EH, Carvalho ES, Mello ES, Filho FM, Coimbra FJF, Capareli FC, Arruda FF, Vieira FMAC, Takeda FR, Cotti GCC, Pereira GLS, Paulo GA, Ribeiro HSC, Lourenco LG, Crosara M, Toneto MG, Oliveira MB, de Lourdes Oliveira M, Begnami MD, Forones NM, Yagi O, Ashton-Prolla P, Aguillar PB, Amaral PCG, Hoff PM, Araujo RLC, Di Paula Filho RP, Gansl RC, Gil RA, Pfiffer TEF, Souza T, Ribeiro U Jr, Jesus VHF, Costa WL Jr, Prolla G. Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of oesophageal cancer. Ecancermedicalscience 2021;15:1195. [PMID: 33889204 DOI: 10.3332/ecancer.2021.1195] [Reference Citation Analysis]
58 Shi J, Li J, Li F, Zhang Y, Guo Y, Wang W, Wang J. Comparison of the Gross Target Volumes Based on Diagnostic PET/CT for Primary Esophageal Cancer. Front Oncol 2021;11:550100. [PMID: 33718127 DOI: 10.3389/fonc.2021.550100] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
59 Li Y, Liu J, Li HX, Cai XW, Li ZG, Ye XD, Teng HH, Fu XL, Yu W. Radiomics Signature Facilitates Organ-Saving Strategy in Patients With Esophageal Squamous Cell Cancer Receiving Neoadjuvant Chemoradiotherapy. Front Oncol 2020;10:615167. [PMID: 33680935 DOI: 10.3389/fonc.2020.615167] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
60 Yang X, Wang L, Du H, Lin B, Yi J, Wen X, Geng L, Du X. Prognostic impact of eosinophils in peripheral blood and tumor site in patients with esophageal squamous cell carcinoma treated with concurrent chemoradiotherapy. Medicine (Baltimore) 2021;100:e24328. [PMID: 33546064 DOI: 10.1097/MD.0000000000024328] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Jeong H, Im HS, Bang Y, Kim YH, Kim HR, Lee HJ, Jung HY, Lee GH, Song HJ, Kim DH, Choi KD, Lee JH, Ahn JY, Na HK, Ryu JS, Kang J, Kim SB, Kim JH, Park SR. Analysis of clinical outcomes and prognostic factors in patients treated with definitive chemoradiotherapy for oesophageal squamous cell carcinoma. Cancer Med 2021;10:1745-58. [PMID: 33590710 DOI: 10.1002/cam4.3783] [Reference Citation Analysis]
62 Ristau J, Thiel M, Katayama S, Schlampp I, Lang K, Häfner MF, Herfarth K, Debus J, Koerber SA. Simultaneous integrated boost concepts in definitive radiation therapy for esophageal cancer: outcomes and toxicity. Radiat Oncol 2021;16:23. [PMID: 33522923 DOI: 10.1186/s13014-021-01749-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
63 Hipp J, Nagavci B, Schmoor C, Meerpohl J, Hoeppner J, Schmucker C. Post-Neoadjuvant Surveillance and Surgery as Needed Compared with Post-Neoadjuvant Surgery on Principle in Multimodal Treatment for Esophageal Cancer: A Scoping Review. Cancers (Basel) 2021;13:429. [PMID: 33561090 DOI: 10.3390/cancers13030429] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Dreyfuss AD, Barsky AR, Wileyto EP, Eads JR, Kucharczuk JC, Williams NN, Karasic TB, Metz JM, Ben-Josef E, Plastaras JP, Wojcieszynski AP. The efficacy and safety of definitive concurrent chemoradiotherapy for non-operable esophageal cancer. Cancer Med 2021;10:1275-88. [PMID: 33474812 DOI: 10.1002/cam4.3724] [Reference Citation Analysis]
65 Pathak R, Canavan ME, Walters S, Salazar MC, Boffa DJ. Chemoradiation as a nonsurgical treatment option for early-stage esophageal cancers: a retrospective cohort study. J Thorac Dis 2021;13:140-8. [PMID: 33569194 DOI: 10.21037/jtd-20-1187] [Reference Citation Analysis]
66 Nayan N, Bhattacharyya M, Jagtap VK, Kalita AK, Sunku R, Roy PS. Standard-dose versus high-dose radiotherapy with concurrent chemotherapy in esophageal cancer: A prospective randomized study. South Asian J Cancer 2018;7:27-30. [PMID: 29600230 DOI: 10.4103/sajc.sajc_178_17] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
67 Dong D, Zhao D, Li S, Liu W, Du F, Xu X, Xiao S, Zheng B, Sun Y, Wang W. Nomogram to predict overall survival for patients with non-metastatic cervical esophageal cancer: a SEER-based population study. Ann Transl Med 2020;8:1588. [PMID: 33437787 DOI: 10.21037/atm-20-2505] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
68 Schlottmann F, Gaber C, Strassle PD, Herbella FAM, Molena D, Patti MG. Disparities in esophageal cancer: less treatment, less surgical resection, and poorer survival in disadvantaged patients. Dis Esophagus 2020;33:doz045. [PMID: 31076759 DOI: 10.1093/dote/doz045] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
69 Jia R, Zhao CH, Li PS, Liu RR, Zhang Y, Chen HE, Chang LP, Gong YH, Guan YF, Yi X, Xu JM. Post-radiation circulating tumor DNA as a prognostic factor in locally advanced esophageal squamous cell carcinoma. Oncol Lett 2021;21:68. [PMID: 33365079 DOI: 10.3892/ol.2020.12329] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
70 Kagami T, Yamade M, Suzuki T, Uotani T, Tani S, Hamaya Y, Iwaizumi M, Osawa S, Sugimoto K, Miyajima H, Baba S, Sugimura H, Murai J, Pommier Y, Furuta T. The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy. BMC Cancer 2020;20:1123. [PMID: 33218331 DOI: 10.1186/s12885-020-07574-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
71 Zhao K, Si Y, Sun L, Meng X, Yu J. Efficacy and toxicity of re-irradiation for esophageal cancer patients with locoregional recurrence: a retrospective analysis. Radiat Oncol 2020;15:243. [PMID: 33087143 DOI: 10.1186/s13014-020-01685-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
72 Li Y, Beck M, Päßler T, Lili C, Hua W, Mai HD, Amthauer H, Biebl M, Thuss-Patience PC, Berger J, Stromberger C, Tinhofer I, Kruppa J, Budach V, Hofheinz F, Lin Q, Zschaeck S. A FDG-PET radiomics signature detects esophageal squamous cell carcinoma patients who do not benefit from chemoradiation. Sci Rep 2020;10:17671. [PMID: 33077841 DOI: 10.1038/s41598-020-74701-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
73 Pao TH, Chang WL, Chiang NJ, Chang JS, Lin CY, Lai WW, Tseng YL, Yen YT, Chung TJ, Lin FC. Cardiac radiation dose predicts survival in esophageal squamous cell carcinoma treated by definitive concurrent chemotherapy and intensity modulated radiotherapy. Radiat Oncol 2020;15:221. [PMID: 32962730 DOI: 10.1186/s13014-020-01664-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
74 Zhang C, Zhang G, Sun N, Zhang Z, Xue L, Zhang Z, Yang H, Luo Y, Zheng X, Zhang Y, Yuan Y, Lei R, Yang Z, Zheng B, Wang L, Che Y, Wang F, Wang S, Gao S, Xue Q, Zhang Y, He J. An individualized immune signature of pretreatment biopsies predicts pathological complete response to neoadjuvant chemoradiotherapy and outcomes in patients with esophageal squamous cell carcinoma. Signal Transduct Target Ther 2020;5:182. [PMID: 32883946 DOI: 10.1038/s41392-020-00221-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
75 Seyedin SN, Gannon MK, Plichta KA, Abushahin L, Berg DJ, Arshava EV, Parekh KR, Keech JC, Caster JM, Welsh JW, Allen BG. Safety and Efficacy of Stereotactic Body Radiation Therapy for Locoregional Recurrences After Prior Chemoradiation for Advanced Esophageal Carcinoma. Front Oncol 2020;10:1311. [PMID: 32850412 DOI: 10.3389/fonc.2020.01311] [Reference Citation Analysis]
76 Zhang C, Zhang Z, Zhang G, Xue L, Yang H, Luo Y, Zheng X, Zhang Y, Yuan Y, Lei R, Yang Z, Zheng B, Zhang Z, Wang L, Che Y, Wang S, Wang F, Fang L, Zeng Q, Li J, Gao S, Xue Q, Sun N, He J. A three-lncRNA signature of pretreatment biopsies predicts pathological response and outcome in esophageal squamous cell carcinoma with neoadjuvant chemoradiotherapy. Clin Transl Med 2020;10:e156. [PMID: 32898328 DOI: 10.1002/ctm2.156] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
77 Lin FC, Chang WL, Chiang NJ, Lin MY, Chung TJ, Pao TH, Lai WW, Tseng YL, Yen YT, Sheu BS. Radiation dose escalation can improve local disease control and survival among esophageal cancer patients with large primary tumor volume receiving definitive chemoradiotherapy. PLoS One 2020;15:e0237114. [PMID: 32760099 DOI: 10.1371/journal.pone.0237114] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
78 Oh D, Kim JH. The Current Evidence on Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma. Korean J Thorac Cardiovasc Surg 2020;53:160-7. [PMID: 32793446 DOI: 10.5090/kjtcs.2020.53.4.160] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
79 Triantafyllou T, Wijnhoven B. Multidisciplinary treatment of esophageal cancer: The role of active surveillance after neoadjuvant chemoradiation. Ann Gastroenterol Surg 2020;4:352-9. [PMID: 32724878 DOI: 10.1002/ags3.12350] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
80 Nam SY, Jeon SW, Lee SJ, Kwon YH, Lee HS, Kim SK. Clinical Factors to Predict the Response to Concurrent Chemoradiotherapy and Survival in Esophageal Cancer Patients. Gut Liver 2020;14:450-8. [PMID: 32000467 DOI: 10.5009/gnl19165] [Reference Citation Analysis]
81 Rades D, Bartscht T, Hunold P, Schmidberger H, König L, Debus J, Belka C, Homann N, Spillner P, Petersen C, Kuhnt T, Fietkau R, Ridwelski K, Karcher-Kilian K, Kranich A, Männikkö S, Schild SE, Maderer A, Moehler M. Radiochemotherapy with or without cetuximab for unresectable esophageal cancer: final results of a randomized phase 2 trial (LEOPARD-2). Strahlenther Onkol 2020;196:795-804. [PMID: 32533228 DOI: 10.1007/s00066-020-01646-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
82 Huang T, Yang J, Liu B, Fu L. A new mouse esophageal cancer cell line (mEC25)-derived pre-clinical syngeneic tumor model for immunotherapy. Cancer Commun (Lond) 2020;40:316-20. [PMID: 32510874 DOI: 10.1002/cac2.12066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
83 Gamboa AC, Meyer BI, Switchenko JM, Rupji M, Lee RM, Turgeon MK, Russell MC, Cardona K, Kooby DA, Maithel SK, Shah MM. Should adenosquamous esophageal cancer be treated like adenocarcinoma or squamous cell carcinoma? J Surg Oncol 2020;122:412-21. [PMID: 32462769 DOI: 10.1002/jso.25990] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
84 Celik E, Baus W, Baues C, Schröder W, Clivio A, Fogliata A, Scorsetti M, Marnitz S, Cozzi L. Volumetric modulated arc therapy versus intensity-modulated proton therapy in neoadjuvant irradiation of locally advanced oesophageal cancer. Radiat Oncol 2020;15:120. [PMID: 32448296 DOI: 10.1186/s13014-020-01570-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
85 Ishikura S, Kondo T, Murai T, Ozawa Y, Yanagi T, Sugie C, Miyakawa A, Shibamoto Y. Definitive chemoradiotherapy for squamous cell carcinoma of the esophagus: outcomes for borderline-resectable disease. J Radiat Res 2020;61:464-9. [PMID: 32249307 DOI: 10.1093/jrr/rraa008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
86 Rahimy E, Koong A, Toesca D, White MN, Panjwani N, Fisher G, Chang D, Pollom E. Outcomes and Tolerability of Definitive and Preoperative Chemoradiation in Elderly Patients With Esophageal Cancer: A Retrospective Institutional Review. Adv Radiat Oncol 2020;5:1188-96. [PMID: 33305080 DOI: 10.1016/j.adro.2020.05.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
87 Korkmaz U, Hacioglu MB, Kostek O, Sut N, Kodaz H, Erdogan B, Ustun F, Saynak M, Tastekin E, Cicin I, Durmus-Altun G. The relationship between FDG PET/CT-defined metabolic parameters and the histopathological subtype of oesophageal carcinomas. Pol J Radiol 2020;85:e254-60. [PMID: 32612724 DOI: 10.5114/pjr.2020.95945] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
88 Bai XH, Dang J, Chen ZQ, He Z, Li G. Comparison between Intensity-Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy for Their Effectiveness in Esophageal Cancer Treatment: A Retrospective Single Institution Study. J Oncol 2020;2020:6582341. [PMID: 32308681 DOI: 10.1155/2020/6582341] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
89 Jung HK, Tae CH, Lee HA, Lee H, Don Choi K, Park JC, Kwon JG, Choi YJ, Hong SJ, Sung J, Chung WC, Kim KB, Kim SY, Song KH, Park KS, Jeon SW, Kim BW, Ryu HS, Lee OJ, Baik GH, Kim YS, Jung HY; Korean College of Helicobacter and Upper Gastrointestinal Research. Treatment pattern and overall survival in esophageal cancer during a 13-year period: A nationwide cohort study of 6,354 Korean patients. PLoS One 2020;15:e0231456. [PMID: 32275699 DOI: 10.1371/journal.pone.0231456] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
90 Zhu LH, Yao J, Wu T, Wang Y, Wang CW, Xue CQ, Wu LG, Fan XW, Wu CY. Risk of Recurrence and Metastasis for Patients with T1N0M0 Esophageal Carcinoma Who Achieve Completed Resection via Endoscopic Submucosal Resection: Evidence for the Appropriateness of the Watch and Wait Follow-Up Strategy. Cancer Manag Res 2020;12:2427-35. [PMID: 32308479 DOI: 10.2147/CMAR.S227959] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
91 Lin CH, Hung TM, Chang YC, Hsieh CH, Shih MC, Huang SM, Yang CK, Chang CF, Chan SC, Yap WK. Prognostic Value of Lymph Node-To-Primary Tumor Standardized Uptake Value Ratio in Esophageal Squamous Cell Carcinoma Treated with Definitive Chemoradiotherapy. Cancers (Basel) 2020;12:E607. [PMID: 32155748 DOI: 10.3390/cancers12030607] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
92 Liu L, Huang C, Liao W, Chen S, Cai S. Smoking behavior and smoking index as prognostic indicators for patients with esophageal squamous cell carcinoma who underwent surgery: A large cohort study in Guangzhou, China. Tob Induc Dis 2020;18:9. [PMID: 32071596 DOI: 10.18332/tid/117428] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
93 Chu J, Niu X, Chang J, Shao M, Peng L, Xi Y, Lin A, Wang C, Cui Q, Luo Y, Fan W, Chen Y, Sun Y, Guo W, Tan W, Lin D, Wu C. Metabolic remodeling by TIGAR overexpression is a therapeutic target in esophageal squamous-cell carcinoma. Theranostics 2020;10:3488-502. [PMID: 32206103 DOI: 10.7150/thno.41427] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
94 Sherry AD, Newman NB, Anderson JL, Osmundson EC. Systemic inflammatory dynamics during chemoradiotherapy predict response, relapse, metastasis, and survival in esophageal carcinoma. J Surg Oncol 2019;121:303-12. [DOI: 10.1002/jso.25793] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
95 Sakin A, Urun YY, Sahin S, Atci MM, Arici S, Geredeli C, Yasar N, Demir C, Cihan S. Factors affecting survival in esophageal squamous cell carcinoma: Single-center experience. North Clin Istanb 2020;7:267-74. [PMID: 32478299 DOI: 10.14744/nci.2019.31384] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
96 Salcedo J, Suen SC, Bian SX. Cost-effectiveness of chemoradiation followed by esophagectomy versus chemoradiation alone in squamous cell carcinoma of the esophagus. Cancer Med 2020;9:440-6. [PMID: 31749330 DOI: 10.1002/cam4.2721] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
97 Anderluh F, Toplak M, Velenik V, Oblak I, Ermenc AS, Peressutti AJ, But-Hadzic J, Vidmar MS. Definitive radiochemotherapy in esophageal cancer - a single institution experience. Radiol Oncol 2019;53:480-7. [PMID: 31747382 DOI: 10.2478/raon-2019-0054] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
98 Azad TD, Chaudhuri AA, Fang P, Qiao Y, Esfahani MS, Chabon JJ, Hamilton EG, Yang YD, Lovejoy A, Newman AM, Kurtz DM, Jin M, Schroers-Martin J, Stehr H, Liu CL, Hui AB, Patel V, Maru D, Lin SH, Alizadeh AA, Diehn M. Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer. Gastroenterology 2020;158:494-505.e6. [PMID: 31711920 DOI: 10.1053/j.gastro.2019.10.039] [Cited by in Crossref: 40] [Cited by in F6Publishing: 68] [Article Influence: 13.3] [Reference Citation Analysis]
99 Huang WT, Lu HI, Wang YM, Chen YH, Lo CM, Lin WC, Lan YC, Tseng LH, Li SH. Positive Programmed Cell Death-Ligand 1 Expression Predicts Poor Treatment Outcomes in Esophageal Squamous Cell Carcinoma Patients Receiving Neoadjuvant Chemoradiotherapy. J Clin Med 2019;8:E1864. [PMID: 31684197 DOI: 10.3390/jcm8111864] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
100 Zhao H, Koyanagi K, Kato K, Ito Y, Itami J, Igaki H, Tachimori Y. Comparison of long-term outcomes between radical esophagectomy and definitive chemoradiotherapy in patients with clinical T1bN0M0 esophageal squamous cell carcinoma. J Thorac Dis 2019;11:4654-62. [PMID: 31903254 DOI: 10.21037/jtd.2019.10.31] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
101 Shah T, Kushnir V, Mutha P, Majhail M, Patel B, Schutzer M, Mogahanaki D, Smallfield G, Patel M, Zfass A. Neoadjuvant cryotherapy improves dysphagia and may impact remission rates in advanced esophageal cancer. Endosc Int Open 2019;7:E1522-7. [PMID: 31681831 DOI: 10.1055/a-0957-2798] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
102 Fassan M, Cavallin F, Guzzardo V, Kotsafti A, Scarpa M, Cagol M, Chiarion-Sileni V, Maria Saadeh L, Alfieri R, Castagliuolo I, Rugge M, Castoro C, Scarpa M. PD-L1 expression, CD8+ and CD4+ lymphocyte rate are predictive of pathological complete response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic esophagus. Cancer Med 2019;8:6036-48. [PMID: 31429521 DOI: 10.1002/cam4.2359] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
103 Fan KH, Chao YK, Chang JT, Tsang NM, Liao CT, Chang KP, Lin CY, Wang HM, Hsu CL, Huang SF. A retrospective analysis of the treatment results for advanced synchronous head and neck and esophageal cancer. BJR Open 2019;1:20190015. [PMID: 33178944 DOI: 10.1259/bjro.20190015] [Reference Citation Analysis]
104 Raman V, Jawitz OK, Voigt SL, Farrow NE, Yang CJ, D'Amico TA, Harpole DH Jr. Surgery Is Associated With Survival Benefit in T4a Esophageal Adenocarcinoma: A National Analysis. Ann Thorac Surg 2019;108:1633-9. [PMID: 31356800 DOI: 10.1016/j.athoracsur.2019.05.091] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
105 Voeten DM, den Bakker CM, Heineman DJ, Ket JCF, Daams F, van der Peet DL. Definitive Chemoradiotherapy Versus Trimodality Therapy for Resectable Oesophageal Carcinoma: Meta-analyses and Systematic Review of Literature. World J Surg 2019;43:1271-85. [PMID: 30607604 DOI: 10.1007/s00268-018-04901-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
106 Wang Q, Zhang W, Zhang B, Zhang H, Zhang J, Pang Q, Wang P. Application of the proposed eighth edition of the American Joint Committee on Cancer/Union of International Cancer Control esophageal cancer staging system in esophageal cancer patients. Prec Radiat Oncol 2019;3:52-8. [DOI: 10.1002/pro6.65] [Reference Citation Analysis]
107 Engel S, Awerbuch A, Kwon D, Picado O, Yechieli R, Yakoub D, Portelance L. Optimal radiation dosing in concurrent neoadjuvant chemoradiation for resectable esophageal cancer: a meta-analysis. J Gastrointest Oncol 2019;10:391-9. [PMID: 31183187 DOI: 10.21037/jgo.2019.01.02] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
108 Kim HK, Ko WJ, Kwon CI, Song GW, Yoo IK, Song JH, Kim HS, Cho JY. Endoscopic Submucosal Dissection Followed by Concurrent Chemoradiotherapy in Patients with Early Esophageal Cancer with a High Risk of Lymph Node Metastasis. Clin Endosc 2019;52:502-5. [PMID: 31085965 DOI: 10.5946/ce.2018.176] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
109 Djuric-Stefanovic A, Jankovic A, Saponjski D, Micev M, Stojanovic-Rundic S, Cosic-Micev M, Pesko P. Analyzing the post-contrast attenuation of the esophageal wall on routine contrast-enhanced MDCT examination can improve the diagnostic accuracy in response evaluation of the squamous cell esophageal carcinoma to neoadjuvant chemoradiotherapy in comparison with the esophageal wall thickness. Abdom Radiol (NY) 2019;44:1722-33. [PMID: 30758534 DOI: 10.1007/s00261-019-01911-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
110 Faiz Z, Plukker JTM. ASO Author Reflections: Implementation of Age and Co-morbidity in the Treatment Guideline of Patients with Esophageal Squamous Cell Carcinoma. Ann Surg Oncol 2019;26:585-6. [PMID: 31011909 DOI: 10.1245/s10434-019-07361-4] [Reference Citation Analysis]
111 Münch S, Pigorsch SU, Devečka M, Dapper H, Feith M, Friess H, Weichert W, Jesinghaus M, Braren R, Combs SE, Habermehl D. Neoadjuvant versus definitive chemoradiation in patients with squamous cell carcinoma of the esophagus. Radiat Oncol 2019;14:66. [PMID: 30992022 DOI: 10.1186/s13014-019-1270-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
112 van den Ende T, Ter Veer E, Mali RMA, van Berge Henegouwen MI, Hulshof MCCM, van Oijen MGH, van Laarhoven HWM. Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis. Cancers (Basel) 2019;11:E530. [PMID: 31013858 DOI: 10.3390/cancers11040530] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
113 Cheng YF, Wang BY, Chen HS. Reply. Ann Thorac Surg 2019;108:963-4. [PMID: 30890418 DOI: 10.1016/j.athoracsur.2019.02.022] [Reference Citation Analysis]
114 Kuo IY, Huang YL, Lin CY, Lin CH, Chang WL, Lai WW, Wang YC. SOX17 overexpression sensitizes chemoradiation response in esophageal cancer by transcriptional down-regulation of DNA repair and damage response genes. J Biomed Sci 2019;26:20. [PMID: 30777052 DOI: 10.1186/s12929-019-0510-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
115 Kim N, Cho H, Yun M, Park KR, Lee CG. Prognostic values of mid-radiotherapy 18F-FDG PET/CT in patients with esophageal cancer. Radiat Oncol 2019;14:27. [PMID: 30717809 DOI: 10.1186/s13014-019-1232-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
116 Faiz Z, van Putten M, Verhoeven RHA, van Sandick JW, Nieuwenhuijzen GAP, van der Sangen MJC, Lemmens VEPP, Wijnhoven BPL, Plukker JTM. Impact of Age and Comorbidity on Choice and Outcome of Two Different Treatment Options for Patients with Potentially Curable Esophageal Cancer. Ann Surg Oncol 2019;26:986-95. [PMID: 30719634 DOI: 10.1245/s10434-019-07181-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
117 Baksh K, Prithviraj G, Kim Y, Hoffe S, Shridhar R, Coppola D, Centeno B, Pimiento J, Meredith K, Almhanna K. Correlation Between Standardized Uptake Value in Preneoadjuvant and Postneoadjuvant Chemoradiotherapy and Tumor Regression Grade in Patients With Locally Advanced Esophageal Cancer. Am J Clin Oncol 2018;41:254-8. [PMID: 26703814 DOI: 10.1097/COC.0000000000000258] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
118 Nakajima M, Muroi H, Kikuchi M. The significance of surgery following concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. J Thorac Dis 2018;10:S3843-5. [PMID: 30631494 DOI: 10.21037/jtd.2018.09.58] [Reference Citation Analysis]
119 Huang YC, Li SH, Lu HI, Hsu CC, Wang YM, Lin WC, Chen CJ, Ho KW, Chiu NT. Post-chemoradiotherapy FDG PET with qualitative interpretation criteria for outcome stratification in esophageal squamous cell carcinoma. PLoS One 2019;14:e0210055. [PMID: 30615636 DOI: 10.1371/journal.pone.0210055] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
120 Yu J, Ouyang W, Li Y, Hu J, Xu Y, Wei Y, Liao Z, Liu Y, Zhang J, Xie C. Value of radiotherapy in addition to esophagectomy for stage II and III thoracic esophageal squamous cell carcinoma: Analysis of surveillance, epidemiology, and end results database. Cancer Med 2019;8:21-7. [PMID: 30561117 DOI: 10.1002/cam4.1731] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
121 Makino T, Yamasaki M, Tanaka K, Miyazaki Y, Takahashi T, Kurokawa Y, Motoori M, Kimura Y, Nakajima K, Mori M, Doki Y. Treatment and clinical outcome of clinical T4 esophageal cancer: A systematic review. Ann Gastroenterol Surg. 2019;3:169-180. [PMID: 30923786 DOI: 10.1002/ags3.12222] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
122 Andreollo NA, Beraldo GC, Alves IPF, Tercioti-Junior V, Ferrer JAP, Coelho-Neto JS, Lopes LR. PATHOLOGIC COMPLETE RESPONSE (YPT0 YPN0) AFTER CHEMOTHERAPY AND RADIOTHERAPY NEOADJUVANT FOLLOWED BY ESOPHAGECTOMY IN THE SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS. Arq Bras Cir Dig 2018;31:e1405. [PMID: 30539980 DOI: 10.1590/0102-672020180001e1405] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
123 Natori A, Chan BA, Sim HW, Ma L, Yokom DW, Chen E, Liu G, Darling G, Swallow C, Brar S, Brierley J, Ringash J, Wong R, Kim J, Rogalla P, Hafezi-Bakhtiari S, Conner J, Knox J, Elimova E, Jang RW. Outcomes by treatment modality in elderly patients with localized gastric and esophageal cancer. Curr Oncol 2018;25:366-70. [PMID: 30607110 DOI: 10.3747/co.25.4208] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
124 Bracken-Clarke D, Farooq AR, Horgan AM. Management of Locally Advanced and Metastatic Esophageal Cancer in the Older Population. Curr Oncol Rep 2018;20:99. [PMID: 30426245 DOI: 10.1007/s11912-018-0745-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
125 Verma V, Sleightholm RL, Fang P, Ryckman JM, Lin C. National Cancer Database report of nonmetastatic esophageal small cell carcinoma. Cancer Med 2018;7:6365-73. [PMID: 30403012 DOI: 10.1002/cam4.1712] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
126 Greally M, Chou JF, Molena D, Rusch VW, Bains MS, Park BJ, Wu AJ, Goodman KA, Kelsen DP, Janjigian YY, Ilson DH, Ku GY. Positron-Emission Tomography Scan-Directed Chemoradiation for Esophageal Squamous Cell Carcinoma: No Benefit for a Change in Chemotherapy in Positron-Emission Tomography Nonresponders. J Thorac Oncol 2019;14:540-6. [PMID: 30391577 DOI: 10.1016/j.jtho.2018.10.152] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
127 Cohen C. ASO Author Reflections: Salvage Surgery for Esophageal Cancer. Ann Surg Oncol 2018;25:960-1. [PMID: 30362068 DOI: 10.1245/s10434-018-6974-8] [Reference Citation Analysis]
128 Nowee ME, Voncken FEM, Kotte ANTJ, Goense L, van Rossum PSN, van Lier ALHMW, Heijmink SW, Aleman BMP, Nijkamp J, Meijer GJ, Lips IM; Dutch National Platform for Radiotherapy of Gastrointestinal Tumours (LPRGE) group. Gross tumour delineation on computed tomography and positron emission tomography-computed tomography in oesophageal cancer: A nationwide study. Clin Transl Radiat Oncol 2019;14:33-9. [PMID: 30519647 DOI: 10.1016/j.ctro.2018.10.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
129 Wang J, Qin J, Jing S, Liu Q, Cheng Y, Wang Y, Cao F. Clinical complete response after chemoradiotherapy for carcinoma of thoracic esophagus: Is esophagectomy always necessary? A systematic review and meta-analysis. Thorac Cancer 2018;9:1638-47. [PMID: 30277016 DOI: 10.1111/1759-7714.12874] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
130 van der Wilk BJ, Eyck BM, Spaander MCW, Valkema R, Lagarde SM, Wijnhoven BPL, van Lanschot JJB. Towards an Organ-Sparing Approach for Locally Advanced Esophageal Cancer. Dig Surg 2019;36:462-9. [PMID: 30227434 DOI: 10.1159/000493435] [Cited by in Crossref: 9] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
131 Jelvehgaran P, Alderliesten T, Georgiou G, Meijer SL, Bloemen PR, Kodach LL, van Laarhoven HWM, van Berge Henegouwen MI, Hulshof MCCM, Rasch CRN, van Leeuwen TG, de Boer JF, de Bruin M, van Herk M. Feasibility of using optical coherence tomography to detect radiation-induced fibrosis and residual cancer extent after neoadjuvant chemo-radiation therapy: an ex vivo study. Biomed Opt Express 2018;9:4196-216. [PMID: 30615728 DOI: 10.1364/BOE.9.004196] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
132 Koëter M, van Putten M, Verhoeven RHA, Lemmens VEPP, Nieuwenhuijzen GAP. Definitive chemoradiation or surgery in elderly patients with potentially curable esophageal cancer in the Netherlands: a nationwide population-based study on patterns of care and survival. Acta Oncol 2018;57:1192-200. [PMID: 29528262 DOI: 10.1080/0284186X.2018.1450521] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
133 Kitagawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, Kawamura O, Kusano M, Kuwano H, Takeuchi H, Toh Y, Doki Y, Naomoto Y, Nemoto K, Booka E, Matsubara H, Miyazaki T, Muto M, Yanagisawa A, Yoshida M. Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1. Esophagus. 2019;16:1-24. [PMID: 30171413 DOI: 10.1007/s10388-018-0641-9] [Cited by in Crossref: 138] [Cited by in F6Publishing: 194] [Article Influence: 34.5] [Reference Citation Analysis]
134 Ma MW, Gao XS, Gu XB, Xie M, Cui M, Zhang M, Liu L, Yin H, Chen LQ. The role of definitive chemoradiotherapy versus surgery as initial treatments for potentially resectable esophageal carcinoma. World J Surg Oncol 2018;16:172. [PMID: 30119684 DOI: 10.1186/s12957-018-1470-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
135 Cheng YF, Chen HS, Wu SC, Chen HC, Hung WH, Lin CH, Wang BY. Esophageal squamous cell carcinoma and prognosis in Taiwan. Cancer Med 2018;7:4193-201. [PMID: 30047253 DOI: 10.1002/cam4.1499] [Cited by in Crossref: 18] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]
136 Tamaki Y, Hieda Y, Nakajima M, Kitajima K, Yoshida R, Yoshizako T, Ue A, Tokudo M, Hirahara N, Moriyama I, Kato H, Inomata T. Concurrent Chemoradiotherapy with Docetaxel, Cisplatin, and 5-fluorouracil Improves Survival of Patients with Advanced Esophageal Cancer Compared with Conventional Concurrent Chemoradiotherapy with Cisplatin and 5-fluorouracil. J Cancer 2018;9:2765-72. [PMID: 30123343 DOI: 10.7150/jca.23456] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
137 Chen CY, Li CC, Chien CR. Neoadjuvant vs definitive concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma patients. World J Surg Oncol 2018;16:141. [PMID: 30007409 DOI: 10.1186/s12957-018-1444-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
138 Tanaka Y, Yoshida K, Suetsugu T, Imai T, Matsuhashi N, Yamaguchi K. Recent advancements in esophageal cancer treatment in Japan. Ann Gastroenterol Surg 2018;2:253-65. [PMID: 30003188 DOI: 10.1002/ags3.12174] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
139 Liu C, Gao X. Determination of radiotherapy target volume for esophageal cancer. Prec Radiat Oncol 2018;2:52-60. [DOI: 10.1002/pro6.37] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
140 Walter F, Böckle D, Schmidt-Hegemann NS, Köpple R, Gerum S, Boeck S, Angele M, Belka C, Roeder F. Clinical outcome of elderly patients (≥ 70 years) with esophageal cancer undergoing definitive or neoadjuvant radio(chemo)therapy: a retrospective single center analysis. Radiat Oncol 2018;13:93. [PMID: 29769143 DOI: 10.1186/s13014-018-1044-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
141 Ferri L. Clinical Complete Response After Neoadjuvant Therapy for Esophageal Cancer: What's Lurking Under the Surface? Ann Surg Oncol 2018;25:2120-1. [PMID: 29761332 DOI: 10.1245/s10434-018-6514-6] [Reference Citation Analysis]
142 Kauppila JH, Mattsson F, Brusselaers N, Lagergren J. Prognosis of oesophageal adenocarcinoma and squamous cell carcinoma following surgery and no surgery in a nationwide Swedish cohort study. BMJ Open. 2018;8:e021495. [PMID: 29748347 DOI: 10.1136/bmjopen-2018-021495] [Cited by in Crossref: 26] [Cited by in F6Publishing: 45] [Article Influence: 6.5] [Reference Citation Analysis]
143 Barbetta A, Nobel TB, Sihag S, Hsu M, Tan KS, Bains MS, Isbell JM, Janjigian YY, Wu AJ, Bott MJ, Jones DR, Molena D. Neutrophil to Lymphocyte Ratio as Predictor of Treatment Response in Esophageal Squamous Cell Cancer. Ann Thorac Surg 2018;106:864-71. [PMID: 29738752 DOI: 10.1016/j.athoracsur.2018.04.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
144 Jimenez-Jimenez E, Mateos P, Aymar N, Roncero R, Ortiz I, Gimenez M, Pardo J, Salinas J, Sabater S. Radiotherapy volume delineation using 18F-FDG-PET/CT modifies gross node volume in patients with oesophageal cancer. Clin Transl Oncol 2018;20:1460-6. [PMID: 29721766 DOI: 10.1007/s12094-018-1879-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
145 Chiu TJ, Lu HI, Chen CH, Huang WT, Wang YM, Lin WC, Li SH. Osteopontin Expression Is Associated with the Poor Prognosis in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Preoperative Chemoradiotherapy. Biomed Res Int 2018;2018:9098215. [PMID: 29854808 DOI: 10.1155/2018/9098215] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
146 Slotta-Huspenina J, Drecoll E, Feith M, Habermehl D, Combs S, Weichert W, Bettstetter M, Becker K, Langer R. MicroRNA expression profiling for the prediction of resistance to neoadjuvant radiochemotherapy in squamous cell carcinoma of the esophagus. J Transl Med. 2018;16:109. [PMID: 29695253 DOI: 10.1186/s12967-018-1492-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
147 Sturm EC, Zahnd WE, Mellinger JD, Ganai S. Survival Implications of Increased Utilization of Local Excision for cT1N0 Esophageal Cancer. Ann Surg 2019;270:295-301. [PMID: 29672407 DOI: 10.1097/SLA.0000000000002782] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
148 Fan B, Fan P, Kong L, Sun X, Zhao S, Sun X, Fu Z, Zheng J, Ma L, Wang S, Hu M, Yu J. 18F-deoxyglucose positron emission tomography/computed tomography to predict local failure in esophageal squamous cell carcinoma. Oncotarget 2017;8:34498-506. [PMID: 28404900 DOI: 10.18632/oncotarget.15606] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
149 Fang P, Musall BC, Son JB, Moreno AC, Hobbs BP, Carter BW, Fellman BM, Mawlawi O, Ma J, Lin SH. Multimodal Imaging of Pathologic Response to Chemoradiation in Esophageal Cancer. Int J Radiat Oncol Biol Phys 2018;102:996-1001. [PMID: 29685377 DOI: 10.1016/j.ijrobp.2018.02.029] [Cited by in Crossref: 20] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
150 Barbetta A, Hsu M, Tan KS, Stefanova D, Herman K, Adusumilli PS, Bains MS, Bott MJ, Isbell JM, Janjigian YY, Ku GY, Park BJ, Wu AJ, Jones DR, Molena D. Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg 2018;155:2710-2721.e3. [PMID: 29548582 DOI: 10.1016/j.jtcvs.2018.01.086] [Cited by in Crossref: 17] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
151 Li CC, Chen CY, Chien CR. Comparative effectiveness of image-guided radiotherapy for non-operated localized esophageal squamous cell carcinoma patients receiving concurrent chemoradiotherapy: A population-based propensity score matched analysis. Oncotarget 2016;7:71548-55. [PMID: 27689398 DOI: 10.18632/oncotarget.12250] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
152 Semenkovich TR, Meyers BF. Surveillance versus esophagectomy in esophageal cancer patients with a clinical complete response after induction chemoradiation. Ann Transl Med 2018;6:81. [PMID: 29666804 DOI: 10.21037/atm.2018.01.31] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
153 Beg MS, Meyer J. Developing rational combinations of immune checkpoint inhibitors and radiation therapy for gastrointestinal cancers. J Gastrointest Oncol. 2018;9:225-230. [PMID: 29564188 DOI: 10.21037/jgo.2017.06.17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
154 Patel SA, Edgington SK, Adams J, Morse C, Ryan DP, Hong TS. Novel use of proton beam therapy for neoadjuvant treatment of radiation-associated squamous cell carcinoma of the esophagus. J Gastrointest Oncol 2019;10:155-60. [PMID: 30788171 DOI: 10.21037/jgo.2018.09.06] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
155 Park IH, Kim JY. Surveillance or resection after chemoradiation in esophageal cancer. Ann Transl Med 2018;6:82. [PMID: 29666805 DOI: 10.21037/atm.2017.12.16] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
156 Deng W, Lin SH. Advances in radiotherapy for esophageal cancer. Ann Transl Med 2018;6:79. [PMID: 29666802 DOI: 10.21037/atm.2017.11.28] [Cited by in Crossref: 12] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
157 Tu CC, Hsu PK. The frontline of esophageal cancer treatment: questions to be asked and answered. Ann Transl Med 2018;6:83. [PMID: 29666806 DOI: 10.21037/atm.2017.10.31] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
158 Li J, Gong Y, Diao P, Huang Q, Wen Y, Lin B, Cai H, Tian H, He B, Ji L, Guo P, Miao J, Du X. Comparison of the clinical efficacy between single-agent and dual-agent concurrent chemoradiotherapy in the treatment of unresectable esophageal squamous cell carcinoma: a multicenter retrospective analysis. Radiat Oncol 2018;13:12. [PMID: 29357883 DOI: 10.1186/s13014-018-0958-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
159 Hegemann NS, Koepple R, Walter F, Boeckle D, Fendler WP, Angele MK, Boeck S, Belka C, Roeder F. Neoadjuvant chemoradiation for esophageal cancer : Surgery improves locoregional control while response based on FDG-PET/CT predicts survival. Strahlenther Onkol 2018;194:435-43. [PMID: 29349603 DOI: 10.1007/s00066-018-1261-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
160 Chan CM, Lai KKY, Ng EKO, Kiang MN, Kwok TWH, Wang HK, Chan KW, Law TT, Tong DK, Chan KT, Lee NP, Law S. Serum microRNA-193b as a promising biomarker for prediction of chemoradiation sensitivity in esophageal squamous cell carcinoma patients. Oncol Lett 2018;15:3273-80. [PMID: 29435069 DOI: 10.3892/ol.2017.7698] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
161 Michalarea V, Smyth EC. Neoadjuvant DCF vs. ACF for resectable oesophageal squamous cell carcinoma. J Thorac Dis 2017;9:2868-70. [PMID: 29221258 DOI: 10.21037/jtd.2017.08.148] [Reference Citation Analysis]
162 Fazio N, Bertani E, Cella CA. Should cT2N0M0 be managed as a localized or locally advanced esophageal carcinoma? J Thorac Dis 2017;9:2829-34. [PMID: 29221250 DOI: 10.21037/jtd.2017.08.82] [Reference Citation Analysis]
163 Wu SX, Li XY, Xu HY, Xu QN, Luo HS, Du ZS, Huang HC, Wu ZY. Effect of consolidation chemotherapy following definitive chemoradiotherapy in patients with esophageal squamous cell cancer. Sci Rep 2017;7:16870. [PMID: 29203855 DOI: 10.1038/s41598-017-17254-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
164 Yap W, Chang Y, Hsieh C, Chao Y, Chen C, Shih M, Hung T. Favorable versus unfavorable prognostic groups by post-chemoradiation FDG-PET imaging in node-positive esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy. Eur J Nucl Med Mol Imaging 2018;45:689-98. [DOI: 10.1007/s00259-017-3901-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
165 Cartwright E, Cunningham D. The Role of Systemic Therapy in Resectable Gastric and Gastro-oesophageal Junction Cancer. Curr Treat Options Oncol 2017;18:69. [PMID: 29143893 DOI: 10.1007/s11864-017-0510-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
166 Vlacich G, Samson PP, Perkins SM, Roach MC, Parikh PJ, Bradley JD, Lockhart AC, Puri V, Meyers BF, Kozower B, Robinson CG. Treatment utilization and outcomes in elderly patients with locally advanced esophageal carcinoma: a review of the National Cancer Database. Cancer Med 2017;6:2886-96. [PMID: 29139215 DOI: 10.1002/cam4.1250] [Cited by in Crossref: 21] [Cited by in F6Publishing: 30] [Article Influence: 4.2] [Reference Citation Analysis]
167 Samuels SE, Stenmark MH, Lee JY, McHugh JB, Hayman JA, Orringer MB, Urba SG, Sun L, Xie C, Kong FM, Cuneo KC. Neoadjuvant twice daily chemoradiotherapy for esophageal cancer: Treatment-related mortality and long-term outcomes. Adv Radiat Oncol 2017;2:308-15. [PMID: 29114597 DOI: 10.1016/j.adro.2017.05.003] [Reference Citation Analysis]
168 Chen F, Luo H, Xing L, Liang N, Xie J, Zhang J. Feasibility and efficiency of concurrent chemoradiotherapy with capecitabine and cisplatin versus radiotherapy alone for elderly patients with locally advanced esophageal squamous cell carcinoma: Experience of two centers. Thorac Cancer 2018;9:59-65. [PMID: 29024498 DOI: 10.1111/1759-7714.12536] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
169 Klempner SJ, Wu W, Mehta P, Schrock AB, Chao J, Ali SM. Genomic Profiling to Expand Management Options for Locally Advanced Esophagogastric Cancers: A Proof of Principle Case. JCO Precis Oncol 2017;1:PO. [PMID: 32913963 DOI: 10.1200/PO.17.00166] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
170 Zhao Q, Hu G, Xiao W, Chen Y, Shen M, Tang Q, Ning X. Comparison of definitive chemoradiotherapy and radiotherapy alone in patients older than 75 years with locally advanced esophageal carcinoma: A retrospective cohort study. Medicine (Baltimore) 2017;96:e7920. [PMID: 28858114 DOI: 10.1097/MD.0000000000007920] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
171 Saigí M, Oliva M, Aliste L, Calvo M, Hormigo G, Serra Ò, Boladeras A, Farran L, Robles J, Creus G, Paúles MJ, Gornals JB, de Lama E, Borràs JM, Sala N, Galán M. Clinical relevance of histologic subtypes in locally advanced esophageal carcinoma treated with pre-operative chemoradiotherapy: Experience of a monographic oncologic centre. PLoS One 2017;12:e0184737. [PMID: 28931046 DOI: 10.1371/journal.pone.0184737] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
172 Luo LL, Xi M, Yang YD, Li QQ, Zhao L, Zhang P, Liu SL, Liu MZ. Comparative Outcomes of Induction Chemotherapy Followed By Definitive Chemoradiotherapy versus Chemoradiotherapy Alone In Esophageal Squamous Cell Carcinoma. J Cancer 2017;8:3441-7. [PMID: 29151927 DOI: 10.7150/jca.21131] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
173 Vellayappan BA, Soon YY, Ku GY, Leong CN, Lu JJ, Tey JC. Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer. Cochrane Database Syst Rev 2017;8:CD010511. [PMID: 28829911 DOI: 10.1002/14651858.CD010511.pub2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 34] [Article Influence: 2.0] [Reference Citation Analysis]
174 Münch S, Oechsner M, Combs SE, Habermehl D. DVH- and NTCP-based dosimetric comparison of different longitudinal margins for VMAT-IMRT of esophageal cancer. Radiat Oncol 2017;12:128. [PMID: 28806990 DOI: 10.1186/s13014-017-0871-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
175 Haefner MF, Lang K, Verma V, Koerber SA, Uhlmann L, Debus J, Sterzing F. Intensity-modulated versus 3-dimensional conformal radiotherapy in the definitive treatment of esophageal cancer: comparison of outcomes and acute toxicity. Radiat Oncol 2017;12:131. [PMID: 28810885 DOI: 10.1186/s13014-017-0863-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
176 Smyth EC, Lagergren J, Fitzgerald RC, Lordick F, Shah MA, Lagergren P, Cunningham D. Oesophageal cancer. Nat Rev Dis Primers. 2017;3:17048. [PMID: 28748917 DOI: 10.1038/nrdp.2017.48] [Cited by in Crossref: 249] [Cited by in F6Publishing: 351] [Article Influence: 49.8] [Reference Citation Analysis]
177 Stahl M, Budach W. Definitive chemoradiotherapy. J Thorac Dis 2017;9:S792-8. [PMID: 28815076 DOI: 10.21037/jtd.2017.05.05] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
178 Chen Y, Zhu HP, Wang T, Sun CJ, Ge XL, Min LF, Zhang XW, Jia QQ, Yu J, Yang JQ, Allgayer H, Abba ML, Zhang XZ, Sun XC. What is the optimal radiation dose for non-operable esophageal cancer? Dissecting the evidence in a meta-analysis. Oncotarget 2017;8:89095-107. [PMID: 29179502 DOI: 10.18632/oncotarget.18760] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
179 Hamamoto Y, Nojima M, Aoki Y, Suzuki T, Kawasaki K, Hirata K, Sukawa Y, Kasuga A, Kawakubo H, Takeuchi H, Murakami K, Takaishi H, Kanai T, Kitagawa Y. Inter-evaluator heterogeneity of clinical diagnosis for locally advanced esophageal squamous cell carcinoma. Esophagus 2017;14:324-32. [PMID: 28983229 DOI: 10.1007/s10388-017-0580-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
180 Xi M, Liao Z, Hofstetter WL, Komaki R, Ho L, Lin SH. 18F-FDG PET Response After Induction Chemotherapy Can Predict Who Will Benefit from Subsequent Esophagectomy After Chemoradiotherapy for Esophageal Adenocarcinoma. J Nucl Med 2017;58:1756-63. [PMID: 28522744 DOI: 10.2967/jnumed.117.192591] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
181 Shi A, Liao Z, Allen PK, Ho L, Murphy MB, Maru DM, Swisher SG, Hofstetter WL, Mehran RJ, Cox JD, Komaki R, Lin SH. Long-term survival and toxicity outcomes of intensity modulated radiation therapy for the treatment of esophageal cancer: A large single-institutional cohort study. Adv Radiat Oncol 2017;2:316-24. [PMID: 29114598 DOI: 10.1016/j.adro.2017.04.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
182 Chen MF, Chen PT, Lu MS, Lee CP, Chen WC. Survival benefit of surgery to patients with esophageal squamous cell carcinoma. Sci Rep 2017;7:46139. [PMID: 28383075 DOI: 10.1038/srep46139] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
183 Lertbutsayanukul C, Tharavej C, Klaikeaw N, Prayongrat A, Lowanitchai C, Sriuranpong V. High dose radiation with chemotherapy followed by salvage esophagectomy among patients with locally advanced esophageal squamous cell carcinoma. Thorac Cancer 2017;8:219-28. [PMID: 28322515 DOI: 10.1111/1759-7714.12427] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
184 Swisher SG, Marks J, Rice D. Salvage esophagectomy for persistent or recurrent disease after definitive chemoradiation. Ann Cardiothorac Surg 2017;6:144-51. [PMID: 28447003 DOI: 10.21037/acs.2017.03.02] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
185 Guo Y, Li J, Zhang P, Shao Q, Xu M, Li Y. Comparative evaluation of target volumes defined by deformable and rigid registration of diagnostic PET/CT to planning CT in primary esophageal cancer. Medicine (Baltimore) 2017;96:e5528. [PMID: 28072693 DOI: 10.1097/MD.0000000000005528] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
186 Crosby T, Hurt CN, Falk S, Gollins S, Staffurth J, Ray R, Bridgewater JA, Geh JI, Cunningham D, Blazeby J, Roy R, Maughan T, Griffiths G, Mukherjee S. Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/- cetuximab in oesophageal cancer. Br J Cancer 2017;116:709-16. [PMID: 28196063 DOI: 10.1038/bjc.2017.21] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 7.2] [Reference Citation Analysis]
187 Zhou XL, Li YQ, Zhu WG, Yu CH, Song YQ, Wang WW, He DC, Tao GZ, Tong YS. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for patients with locally advanced esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Sci Rep 2017;7:42581. [PMID: 28195186 DOI: 10.1038/srep42581] [Cited by in Crossref: 21] [Cited by in F6Publishing: 31] [Article Influence: 4.2] [Reference Citation Analysis]
188 Li T, Zhang W, Lv J, Liu H, Wang Q, Jia X, Liu B, Lang J. Safety and outcome of external beam radiation and neutron brachytherapy in elderly patients with esophageal squamous cell cancer. J Contemp Brachytherapy 2017;9:36-43. [PMID: 28344602 DOI: 10.5114/jcb.2017.65839] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
189 Lin D, Ma L, Ye T, Pan Y, Shao L, Song Z, Jiang S, Chen H, Xiang J. Results of neoadjuvant therapy followed by esophagectomy for patients with locally advanced thoracic esophageal squamous cell carcinoma. J Thorac Dis 2017;9:318-26. [PMID: 28275480 DOI: 10.21037/jtd.2017.02.19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
190 Martin-Richard M, Díaz Beveridge R, Arrazubi V, Alsina M, Galan Guzmán M, Custodio AB, Gómez C, Muñoz FL, Pazo R, Rivera F. SEOM Clinical Guideline for the diagnosis and treatment of esophageal cancer (2016). Clin Transl Oncol 2016;18:1179-86. [PMID: 27900538 DOI: 10.1007/s12094-016-1577-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
191 Yokota T, Kato K, Hamamoto Y, Tsubosa Y, Ogawa H, Ito Y, Hara H, Ura T, Kojima T, Chin K, Hironaka S, Kii T, Kojima Y, Akutsu Y, Matsushita H, Kawakami K, Mori K, Nagai Y, Asami C, Kitagawa Y. Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer. Br J Cancer. 2016;115:1328-1334. [PMID: 27811857 DOI: 10.1038/bjc.2016.350] [Cited by in Crossref: 56] [Cited by in F6Publishing: 59] [Article Influence: 9.3] [Reference Citation Analysis]
192 Verma V, Moreno AC, Lin SH. Advances in Radiotherapy Management of Esophageal Cancer. J Clin Med 2016;5:E91. [PMID: 27775643 DOI: 10.3390/jcm5100091] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
193 Gemici C, Yaprak G, Batirel HF, Ilhan M, Mayadagli A. Radiation field size and dose determine oncologic outcome in esophageal cancer. World J Surg Oncol 2016;14:263. [PMID: 27737673 DOI: 10.1186/s12957-016-1024-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
194 Swisher SG, Moughan J, Komaki RU, Ajani JA, Wu TT, Hofstetter WL, Konski AA, Willett CG. Final Results of NRG Oncology RTOG 0246: An Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation. J Thorac Oncol 2017;12:368-74. [PMID: 27729298 DOI: 10.1016/j.jtho.2016.10.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 5.5] [Reference Citation Analysis]
195 Gockel I, Hoffmeister A, Lordick F. [Neoadjuvant therapy for tumors of the upper gastrointestinal tract : Complication management]. Chirurg 2015;86:1014-22. [PMID: 26374651 DOI: 10.1007/s00104-015-0077-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
196 Nakajo M, Jinguji M, Nakabeppu Y, Nakajo M, Higashi R, Fukukura Y, Sasaki K, Uchikado Y, Natsugoe S, Yoshiura T. Texture analysis of 18F-FDG PET/CT to predict tumour response and prognosis of patients with esophageal cancer treated by chemoradiotherapy. Eur J Nucl Med Mol Imaging 2017;44:206-14. [PMID: 27613542 DOI: 10.1007/s00259-016-3506-2] [Cited by in Crossref: 59] [Cited by in F6Publishing: 66] [Article Influence: 9.8] [Reference Citation Analysis]
197 Bernards N, Haj Mohammad N, Creemers GJ, Rozema T, Roukema JA, Nieuwenhuijzen GA, van Laarhoven HW, van der Sangen M, Lemmens VE. Improvement in survival for patients with synchronous metastatic esophageal cancer in the south of the Netherlands from 1994 to 2013. Acta Oncol 2016;55:1161-7. [PMID: 27174793 DOI: 10.1080/0284186X.2016.1176249] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
198 Namm JP, Posner MC. Transhiatal Esophagectomy for Esophageal Cancer. J Laparoendosc Adv Surg Tech A 2016;26:752-6. [PMID: 27548444 DOI: 10.1089/lap.2016.29009.jpn] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
199 Molena D, Stem M, Blackford AL, Lidor AO. Esophageal Cancer Treatment Is Underutilized Among Elderly Patients in the USA. J Gastrointest Surg 2017;21:126-36. [PMID: 27527093 DOI: 10.1007/s11605-016-3229-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
200 van Rossum PSN, Fried DV, Zhang L, Hofstetter WL, Ho L, Meijer GJ, Carter BW, Court LE, Lin SH. The value of 18F-FDG PET before and after induction chemotherapy for the early prediction of a poor pathologic response to subsequent preoperative chemoradiotherapy in oesophageal adenocarcinoma. Eur J Nucl Med Mol Imaging 2017;44:71-80. [PMID: 27511188 DOI: 10.1007/s00259-016-3478-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
201 Kim GJ, Koshy M, Hanlon AL, Horiba MN, Edelman MJ, Burrows WM, Battafarano RJ, Suntharalingam M. The Benefit of Chemotherapy in Esophageal Cancer Patients With Residual Disease After Trimodality Therapy. Am J Clin Oncol 2016;39:136-41. [PMID: 24487417 DOI: 10.1097/COC.0000000000000036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
202 Chen HS, Hung WH, Ko JL, Hsu PK, Liu CC, Wu SC, Lin CH, Wang BY. Impact of Treatment Modalities on Survival of Patients With Locoregional Esophageal Squamous-Cell Carcinoma in Taiwan. Medicine (Baltimore) 2016;95:e3018. [PMID: 26962818 DOI: 10.1097/MD.0000000000003018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
203 Liu Y, Xiong Z, Beasley A, D'Amico T, Chen XL. Personalized and targeted therapy of esophageal squamous cell carcinoma: an update. Ann N Y Acad Sci 2016;1381:66-73. [PMID: 27399176 DOI: 10.1111/nyas.13144] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
204 Matsuda S, Takeuchi H, Kawakubo H, Ando N, Kitagawa Y. Current Advancement in Multidisciplinary Treatment for Resectable cStage II/III Esophageal Squamous Cell Carcinoma in Japan. Ann Thorac Cardiovasc Surg 2016;22:275-83. [PMID: 27384595 DOI: 10.5761/atcs.ra.16-00111] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
205 Fulton BA, Gray J, McDonald A, McIntosh D, MacLaren V, Hennessy A, Grose D. Single centre outcomes from definitive chemo-radiotherapy and single modality radiotherapy for locally advanced oesophageal cancer. J Gastrointest Oncol 2016;7:166-72. [PMID: 27034782 DOI: 10.3978/j.issn.2078-6891.2015.068] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
206 Best LM, Mughal M, Gurusamy KS. Non-surgical versus surgical treatment for oesophageal cancer. Cochrane Database Syst Rev 2016;3:CD011498. [PMID: 27021481 DOI: 10.1002/14651858.CD011498.pub2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
207 Cho CJ, Song HJ, Lee GH, Choi KD, Kim YH, Ryu JS, Kim SB, Kim JH, Park SI, Jung HY. Clinical implications of endoscopic ultrasonography non-traversability in patients with locoregional esophageal cancer receiving multimodality therapy. Korean J Intern Med 2017;32:443-51. [PMID: 26972059 DOI: 10.3904/kjim.2015.185] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
208 Hong JH, Kim HH, Han EJ, Byun JH, Jang HS, Choi EK, Kang JH, Yoo IeR. Total Lesion Glycolysis Using ¹⁸F-FDG PET/CT as a Prognostic Factor for Locally Advanced Esophageal Cancer. J Korean Med Sci 2016;31:39-46. [PMID: 26770036 DOI: 10.3346/jkms.2016.31.1.39] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
209 Hwang C, Youn YH, Choi SE, Jung YH, Park HY, Park JJ, Kim JH, Park H. Endoscopic Submucosal Dissection for Recurrent or Residual Superficial Esophageal Cancer after Chemoradiotherapy: Two Cases. Clin Endosc 2015;48:553-7. [PMID: 26668804 DOI: 10.5946/ce.2015.48.6.553] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
210 Cho JH, Kim TN. Long-term survival after concurrent chemoradiation therapy for esophageal cancer with tracheal invasion. Korean J Intern Med 2015;30:931-3. [PMID: 26552472 DOI: 10.3904/kjim.2015.30.6.931] [Reference Citation Analysis]
211 Fokas E, Rödel C. Definitive, Preoperative, and Palliative Radiation Therapy of Esophageal Cancer. Viszeralmedizin 2015;31:347-53. [PMID: 26989391 DOI: 10.1159/000440638] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
212 Tao CJ, Lin G, Xu YP, Mao WM. Predicting the Response of Neoadjuvant Therapy for Patients with Esophageal Carcinoma: an In-depth Literature Review. J Cancer 2015;6:1179-86. [PMID: 26516367 DOI: 10.7150/jca.12346] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
213 Yamashita H, Takenaka R, Omori M, Imae T, Okuma K, Ohtomo K, Nakagawa K. Involved-field radiotherapy (IFRT) versus elective nodal irradiation (ENI) in combination with concurrent chemotherapy for 239 esophageal cancers: a single institutional retrospective study. Radiat Oncol 2015;10:171. [PMID: 26269033 DOI: 10.1186/s13014-015-0482-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
214 Molena D, Mungo B, Stem M, Poupore AK, Chen SY, Lidor AO. Does Quality of Care Matter? A Study of Adherence to National Comprehensive Cancer Network Guidelines for Patients with Locally Advanced Esophageal Cancer. J Gastrointest Surg 2015;19:1739-47. [PMID: 26245634 DOI: 10.1007/s11605-015-2899-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
215 Däster S, Soysal SD, Stoll L, Peterli R, von Flüe M, Ackermann C. Long-term quality of life after Ivor Lewis esophagectomy for esophageal cancer. World J Surg. 2014;38:2345-2351. [PMID: 24756548 DOI: 10.1007/s00268-014-2576-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
216 O'Sullivan KE, Hurley ET, Hurley JP. Understanding Complete Pathologic Response in Oesophageal Cancer: Implications for Management and Survival. Gastroenterol Res Pract 2015;2015:518281. [PMID: 26246803 DOI: 10.1155/2015/518281] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
217 Bollschweiler E, Hölscher AH, Schmidt M, Warnecke-Eberz U. Neoadjuvant treatment for advanced esophageal cancer: response assessment before surgery and how to predict response to chemoradiation before starting treatment. Chin J Cancer Res 2015;27:221-30. [PMID: 26157318 DOI: 10.3978/j.issn.1000-9604.2015.04.04] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
218 Hsu FM, Cheng JC, Chang YL, Lee JM, Koong AC, Chuang EY. Circulating mRNA Profiling in Esophageal Squamous Cell Carcinoma Identifies FAM84B As A Biomarker In Predicting Pathological Response to Neoadjuvant Chemoradiation. Sci Rep 2015;5:10291. [PMID: 25980316 DOI: 10.1038/srep10291] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
219 Haefner MF, Lang K, Krug D, Koerber SA, Uhlmann L, Kieser M, Debus J, Sterzing F. Prognostic factors, patterns of recurrence and toxicity for patients with esophageal cancer undergoing definitive radiotherapy or chemo-radiotherapy. J Radiat Res 2015;56:742-9. [PMID: 25907360 DOI: 10.1093/jrr/rrv022] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
220 Allum WH, Bonavina L, Cassivi SD, Cuesta MA, Dong ZM, Felix VN, Figueredo E, Gatenby PA, Haverkamp L, Ibraev MA, Krasna MJ, Lambert R, Langer R, Lewis MP, Nason KS, Parry K, Preston SR, Ruurda JP, Schaheen LW, Tatum RP, Turkin IN, van der Horst S, van der Peet DL, van der Sluis PC, van Hillegersberg R, Wormald JC, Wu PC, Zonderhuis BM. Surgical treatments for esophageal cancers. Ann N Y Acad Sci. 2014;1325:242-268. [PMID: 25266029 DOI: 10.1111/nyas.12533] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
221 Kim YH, Song SY, Shim HJ, Chung WK, Ahn SJ, Yoon MS, Jeong JU, Song JY, Nam TK. Treatment outcomes of neoadjuvant concurrent chemoradiotherapy followed by esophagectomy for patients with esophageal cancer. Radiat Oncol J 2015;33:12-20. [PMID: 25874173 DOI: 10.3857/roj.2015.33.1.12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
222 Schmidt T, Sisic L, Sterzing F, Haag GM, Kunzmann R, Grenacher L, Weichert W, Jäger D, Büchler MW, Ott K. [Salvage surgery in esophageal cancer : Feasibility in patients after definitive radiochemotherapy (> 50 Gy)]. Chirurg 2015;86:955-62. [PMID: 25715974 DOI: 10.1007/s00104-014-2971-z] [Reference Citation Analysis]
223 Zhou ZG, Zhen CJ, Bai WW, Zhang P, Qiao XY, Liang JL, Gao XS, Wang SS. Salvage radiotherapy in patients with local recurrent esophageal cancer after radical radiochemotherapy. Radiat Oncol 2015;10:54. [PMID: 25888966 DOI: 10.1186/s13014-015-0358-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
224 Lin SH, Wang J, Allen PK, Correa AM, Maru DM, Swisher SG, Hofstetter WL, Liao Z, Ajani JA. A nomogram that predicts pathologic complete response to neoadjuvant chemoradiation also predicts survival outcomes after definitive chemoradiation for esophageal cancer. J Gastrointest Oncol 2015;6:45-52. [PMID: 25642337 DOI: 10.3978/j.issn.2078-6891.2014.054] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
225 Wu AJ, Goodman KA. Clinical tools to predict outcomes in patients with esophageal cancer treated with definitive chemoradiation: are we there yet? J Gastrointest Oncol 2015;6:53-9. [PMID: 25642338 DOI: 10.3978/j.issn.2078-6891.2014.099] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
226 Lin J, Kligerman S, Goel R, Sajedi P, Suntharalingam M, Chuong MD. State-of-the-art molecular imaging in esophageal cancer management: implications for diagnosis, prognosis, and treatment. J Gastrointest Oncol 2015;6:3-19. [PMID: 25642333 DOI: 10.3978/j.issn.2078-6891.2014.062] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
227 Zhang WW, Zhu YJ, Yang H, Wang QX, Wang XH, Xiao WW, Li QQ, Liu MZ, Hu YH. Concurrent radiotherapy and weekly chemotherapy of 5-fluorouracil and platinum agents for postoperative locoregional recurrence of oesophageal squamous cell carcinoma. Sci Rep 2015;5:8071. [PMID: 25627119 DOI: 10.1038/srep08071] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
228 Fakhrian K, Ordu AD, Lordick F, Theisen J, Haller B, Omrčen T, Molls M, Nieder C, Geinitz H. Long-term outcomes of trimodality treatment for squamous cell carcinoma of the esophagus with cisplatin and/or 5-FU: more than 20 years' experience at a single institution. Strahlenther Onkol 2014;190:1133-40. [PMID: 25015426 DOI: 10.1007/s00066-014-0711-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
229 Lim JH, Lee SA, Kang GE, Kim JM, Park JK, Chung YJ, Jung JK, Park CK, Kim HS, Lee DW. Esophageal cancer treated by endoscopic submucosal dissection after neoadjuvant chemoradiotherapy: a case report. J Med Case Rep 2014;8:439. [PMID: 25519497 DOI: 10.1186/1752-1947-8-439] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
230 Ordu AD, Nieder C, Geinitz H, Kup PG, Deymann LF, Scherer V, Combs SE, Fakhrian K. Radio(chemo)therapy for locally advanced squamous cell carcinoma of the esophagus: long-term outcome. Strahlenther Onkol. 2015;191:153-160. [PMID: 25404062 DOI: 10.1007/s00066-014-0779-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
231 Duan XF, Tang P, Yu ZT. Neoadjuvant chemoradiotherapy for resectable esophageal cancer: an in-depth study of randomized controlled trials and literature review. Cancer Biol Med. 2014;11:191-201. [PMID: 25364580 DOI: 10.7497/j.issn.2095-3941.2014.03.005] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
232 Shen Y, Tantai J, Zhao H. Ranking candidate genes of esophageal squamous cell carcinomas based on differentially expressed genes and the topological properties of the co-expression network. Eur J Med Res 2014;19:52. [PMID: 25358439 DOI: 10.1186/s40001-014-0052-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
233 Jeong Y, Kim JH. WITHDRAWN: Multimodality treatment for locally advanced esophageal cancers. Gastrointestinal Intervention 2014. [DOI: 10.1016/j.gii.2014.09.003] [Reference Citation Analysis]
234 Saigusa S, Tanaka K, Ohi M, Toiyama Y, Yasuda H, Kitajima T, Okugawa Y, Inoue Y, Mohri Y, Kusunoki M. Clinical implications of Fas/Fas ligand expression in patients with esophageal squamous cell carcinoma following neoadjuvant chemoradiotherapy. Mol Clin Oncol 2015;3:151-6. [PMID: 25469286 DOI: 10.3892/mco.2014.431] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
235 Brücher BL, Kitajima M, Siewert JR. Undervalued criteria in the evaluation of multimodal trials for upper GI cancers. Cancer Invest 2014;32:497-506. [PMID: 25250506 DOI: 10.3109/07357907.2014.958497] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
236 Tai P, Yu E. Esophageal cancer management controversies: Radiation oncology point of view. World J Gastrointest Oncol 2014; 6(8): 263-274 [PMID: 25132924 DOI: 10.4251/wjgo.v6.i8.263] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
237 Shridhar R, Imani-Shikhabadi R, Davis B, Streeter OA, Thomas CR Jr. Curative treatment of esophageal cancer; an evidenced based review. J Gastrointest Cancer 2013;44:375-84. [PMID: 23824628 DOI: 10.1007/s12029-013-9511-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
238 Gupta A, Roy S, Majumdar A, Hazra A, Mallik C. A randomized study to compare sequential chemoradiotherapy with concurrent chemoradiotherapy for unresectable locally advanced esophageal cancer. Indian J Med Paediatr Oncol 2014;35:54-9. [PMID: 25006285 DOI: 10.4103/0971-5851.133722] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
239 Wilson JM, Partridge M, Hawkins M. The application of functional imaging techniques to personalise chemoradiotherapy in upper gastrointestinal malignancies. Clin Oncol (R Coll Radiol) 2014;26:581-96. [PMID: 24998430 DOI: 10.1016/j.clon.2014.06.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
240 Lloyd S, Chang BW. Current strategies in chemoradiation for esophageal cancer. J Gastrointest Oncol 2014;5:156-65. [PMID: 24982764 DOI: 10.3978/j.issn.2078-6891.2014.033] [Cited by in F6Publishing: 23] [Reference Citation Analysis]
241 Berry MF. Esophageal cancer: staging system and guidelines for staging and treatment. J Thorac Dis. 2014;6 Suppl 3:S289-S297. [PMID: 24876933 DOI: 10.3978/j.issn.2072-1439.2014.03.11] [Cited by in F6Publishing: 67] [Reference Citation Analysis]
242 Reimers MS, Engels CC, Kuppen PJ, van de Velde CJ, Liefers GJ. How does genome sequencing impact surgery? Nat Rev Clin Oncol 2014;11:610-8. [PMID: 24958181 DOI: 10.1038/nrclinonc.2014.101] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
243 D’Journo XB, Thomas PA. Current management of esophageal cancer. J Thorac Dis. 2014;6 Suppl 2:S253-S264. [PMID: 24868443 DOI: 10.3978/j.issn.2072-1439.2014.04.16] [Cited by in F6Publishing: 61] [Reference Citation Analysis]
244 Hofstetter WL. Salvage esophagectomy. J Thorac Dis 2014;6 Suppl 3:S341-9. [PMID: 24876940 DOI: 10.3978/j.issn.2072-1439.2014.03.29] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
245 Blazeby JM, Strong S, Donovan JL, Wilson C, Hollingworth W, Crosby T, Nicklin J, Falk SJ, Barham CP, Hollowood AD, Streets CG, Titcomb D, Krysztopik R, Griffin SM, Brookes ST. Feasibility RCT of definitive chemoradiotherapy or chemotherapy and surgery for oesophageal squamous cell cancer. Br J Cancer 2014;111:234-40. [PMID: 24921919 DOI: 10.1038/bjc.2014.313] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
246 Witek M, Blomain ES, Magee MS, Xiang B, Waldman SA, Snook AE. Tumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C. Int J Radiat Oncol Biol Phys 2014;88:1188-95. [PMID: 24661671 DOI: 10.1016/j.ijrobp.2013.12.043] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
247 Nguyen NP, Jang S, Vock J, Vinh-Hung V, Chi A, Vos P, Pugh J, Vo RA, Ceizyk M, Desai A. Feasibility of intensity-modulated and image-guided radiotherapy for locally advanced esophageal cancer. BMC Cancer. 2014;14:265. [PMID: 24742268 DOI: 10.1186/1471-2407-14-265] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
248 Fakhrian K, Ordu AD, Haller B, Theisen J, Lordick F, Bišof V, Molls M, Geinitz H. Cisplatin- vs. oxaliplatin-based radiosensitizing chemotherapy for squamous cell carcinoma of the esophagus: a comparison of two preoperative radiochemotherapy regimens. Strahlenther Onkol 2014;190:987-92. [PMID: 24737541 DOI: 10.1007/s00066-014-0661-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
249 Dorth JA, Pura JA, Palta M, Willett CG, Uronis HE, D'Amico TA, Czito BG. Patterns of recurrence after trimodality therapy for esophageal cancer. Cancer 2014;120:2099-105. [PMID: 24711267 DOI: 10.1002/cncr.28703] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
250 Won E, Ilson DH. Management of localized esophageal cancer in the older patient. Oncologist 2014;19:367-74. [PMID: 24664485 DOI: 10.1634/theoncologist.2013-0178] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
251 Rawat S, Kumar G, Kakria A, Sharma MK, Chauhan D. Chemoradiotherapy in the management of locally advanced squamous cell carcinoma esophagus: is surgical resection required? J Gastrointest Cancer 2013;44:277-84. [PMID: 23389866 DOI: 10.1007/s12029-013-9477-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
252 Gao Z, Meng X, Mu D, Sun X, Yu J. Prognostic significance of epidermal growth factor receptor in locally advanced esophageal squamous cell carcinoma for patients receiving chemoradiotherapy. Oncol Lett 2014;7:1118-22. [PMID: 24944678 DOI: 10.3892/ol.2014.1881] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
253 Fujita H. History of lymphadenectomy for esophageal cancer and the future prospects for esophageal cancer surgery. Surg Today 2015;45:140-9. [PMID: 24519395 DOI: 10.1007/s00595-014-0841-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
254 Quint LE, Reddy RM, Lin J, Arenberg DA, Speers C, Hayman JA, Kong FP, Orringer MB, Kalemkerian GP. Imaging in thoracic oncology: case studies from Multidisciplinary Thoracic Tumor Board: (part 2 of 2 part series). Cancer Imaging 2013;13:440-7. [PMID: 24325879 DOI: 10.1102/1470-7330.2013.0030] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
255 Yan H, Wang R, Jiang S, Zhu K, Feng R, Xu X, Meng X. NSE can predict the sensitivity to definitive chemoradiotherapy of small cell carcinoma of esophagus. Med Oncol 2014;31:796. [PMID: 24307347 DOI: 10.1007/s12032-013-0796-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
256 du Rieu MC, Filleron T, Beluchon B, Humeau M, Julio CH, Bloom E, Ghouti L, Kirzin S, Portier G, Pradère B, Carrère N. Recurrence risk after Ivor Lewis oesophagectomy for cancer. J Cardiothorac Surg 2013;8:215. [PMID: 24261787 DOI: 10.1186/1749-8090-8-215] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
257 Zhang H, Tan S, Chen W, Kligerman S, Kim G, D'Souza WD, Suntharalingam M, Lu W. Modeling pathologic response of esophageal cancer to chemoradiation therapy using spatial-temporal 18F-FDG PET features, clinical parameters, and demographics. Int J Radiat Oncol Biol Phys 2014;88:195-203. [PMID: 24189128 DOI: 10.1016/j.ijrobp.2013.09.037] [Cited by in Crossref: 57] [Cited by in F6Publishing: 61] [Article Influence: 6.3] [Reference Citation Analysis]
258 Stahl M, Ruhstaller T. [Combined modality treatment of oesophageal cancer]. Internist (Berl) 2014;55:7-8, 10-4. [PMID: 24154497 DOI: 10.1007/s00108-013-3315-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
259 Mirza A, Pritchard S, Welch I. Is surgery in the elderly for oesophageal cancer justifiable? Results from a single centre. ISRN Surg 2013;2013:609252. [PMID: 24205444 DOI: 10.1155/2013/609252] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
260 Worni M, Castleberry AW, Gloor B, Pietrobon R, Haney JC, D'Amico TA, Akushevich I, Berry MF. Trends and outcomes in the use of surgery and radiation for the treatment of locally advanced esophageal cancer: a propensity score adjusted analysis of the surveillance, epidemiology, and end results registry from 1998 to 2008. Dis Esophagus 2014;27:662-9. [PMID: 23937253 DOI: 10.1111/dote.12123] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
261 Wiedmann MW, Mössner J. New and emerging combination therapies for esophageal cancer. Cancer Manag Res 2013;5:133-46. [PMID: 23869177 DOI: 10.2147/CMAR.S32199] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
262 Murphy CC, Correa AM, Ajani JA, Komaki RU, Welsh JW, Swisher SG, Hofstetter WL. Surgery is an essential component of multimodality therapy for patients with locally advanced esophageal adenocarcinoma. J Gastrointest Surg 2013;17:1359-69. [PMID: 23715646 DOI: 10.1007/s11605-013-2223-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
263 Palie O, Michel P, Ménard JF, Rousseau C, Rio E, Bridji B, Benyoucef A, Meyer ME, Jalali K, Bardet S, M'vondo CM, Olivier P, Faure G, Itti E, Diana C, Houzard C, Mornex F, Di Fiore F, Vera P. The predictive value of treatment response using FDG PET performed on day 21 of chemoradiotherapy in patients with oesophageal squamous cell carcinoma. A prospective, multicentre study (RTEP3). Eur J Nucl Med Mol Imaging 2013;40:1345-55. [PMID: 23715903 DOI: 10.1007/s00259-013-2450-7] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
264 Liu J, Yue J, Xing L, Yu J. Present status and progress of neoadjuvant chemoradiotherapy for esophageal cancer. Front Med. 2013;7:172-179. [PMID: 23681891 DOI: 10.1007/s11684-013-0268-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
265 Konieczny A, Meyer P, Schnider A, Komminoth P, Schmid M, Lombriser N, Weishaupt D. Accuracy of multidetector-row CT for restaging after neoadjuvant treatment in patients with oesophageal cancer. Eur Radiol. 2013;23:2492-2502. [PMID: 23645329 DOI: 10.1007/s00330-013-2844-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
266 Shah MA. Unanswered Questions in the Management of Gastroesophageal Junction Adenocarcinoma: An Overview from the Medical Oncologist's Perspective. American Society of Clinical Oncology Educational Book 2013. [DOI: 10.14694/edbook_am.2013.33.e155] [Reference Citation Analysis]
267 De Cobelli F, Giganti F, Orsenigo E, Cellina M, Esposito A, Agostini G, Albarello L, Mazza E, Ambrosi A, Socci C, Staudacher C, Del Maschio A. Apparent diffusion coefficient modifications in assessing gastro-oesophageal cancer response to neoadjuvant treatment: Comparison with tumour regression grade at histology. Eur Radiol. 2013;23:2165-2174. [PMID: 23588582 DOI: 10.1007/s00330-013-2807-0] [Cited by in Crossref: 65] [Cited by in F6Publishing: 79] [Article Influence: 7.2] [Reference Citation Analysis]
268 Atsumi K, Nakamura K, Abe K, Hirakawa M, Shioyama Y, Sasaki T, Baba S, Isoda T, Ohga S, Yoshitake T, Shinoto M, Asai K, Honda H. Prediction of outcome with FDG-PET in definitive chemoradiotherapy for esophageal cancer. J Radiat Res 2013;54:890-8. [PMID: 23520267 DOI: 10.1093/jrr/rrt021] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
269 Chen CZ, Chen JZ, Li DR, Lin ZX, Zhou MZ, Li DS, Chen ZJ. Long-term outcomes and prognostic factors for patients with esophageal cancer following radiotherapy. World J Gastroenterol 2013; 19(10): 1639-1644 [PMID: 23539205 DOI: 10.3748/wjg.v19.i10.1639] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
270 Khangura SK, Greenwald BD. Endoscopic management of esophageal cancer after definitive chemoradiotherapy. Dig Dis Sci. 2013;58:1477-1485. [PMID: 23325163 DOI: 10.1007/s10620- 012-2554-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
271 Schweigert M, Dubecz A, Stein HJ. Oesophageal cancer--an overview. Nat Rev Gastroenterol Hepatol. 2013;10:230-244. [PMID: 23296250 DOI: 10.1038/nrgastro.2012.236] [Cited by in Crossref: 55] [Cited by in F6Publishing: 63] [Article Influence: 6.1] [Reference Citation Analysis]
272 Worni M, Martin J, Gloor B, Pietrobon R, D'Amico TA, Akushevich I, Berry MF. Does surgery improve outcomes for esophageal squamous cell carcinoma? An analysis using the surveillance epidemiology and end results registry from 1998 to 2008. J Am Coll Surg 2012;215:643-51. [PMID: 23084493 DOI: 10.1016/j.jamcollsurg.2012.07.006] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 3.9] [Reference Citation Analysis]
273 Tejani MA, Burtness BA. Multi-modality therapy for cancer of the esophagus and GE junction. Curr Treat Options Oncol 2012;13:390-402. [PMID: 22592595 DOI: 10.1007/s11864-012-0193-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
274 Villaflor VM, Allaix ME, Minsky B, Herbella FA, Patti MG. Multidisciplinary approach for patients with esophageal cancer. World J Gastroenterol 2012; 18(46): 6737-6746 [PMID: 23239911 DOI: 10.3748/wjg.v18.i46.6737] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
275 Blank S, Stange A, Sisic L, Roth W, Grenacher L, Sterzing F, Burian M, Jäger D, Büchler M, Ott K. Preoperative therapy of esophagogastric cancer: the problem of nonresponding patients. Langenbecks Arch Surg 2013;398:211-20. [PMID: 23224565 DOI: 10.1007/s00423-012-1034-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
276 Tan S, Kligerman S, Chen W, Lu M, Kim G, Feigenberg S, D'Souza WD, Suntharalingam M, Lu W. Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy. Int J Radiat Oncol Biol Phys 2013;85:1375-82. [PMID: 23219566 DOI: 10.1016/j.ijrobp.2012.10.017] [Cited by in Crossref: 100] [Cited by in F6Publishing: 109] [Article Influence: 10.0] [Reference Citation Analysis]
277 Mawhinney MR, Glasgow RE. Current treatment options for the management of esophageal cancer. Cancer Manag Res 2012;4:367-77. [PMID: 23152702 DOI: 10.2147/CMAR.S27593] [Cited by in Crossref: 4] [Cited by in F6Publishing: 15] [Article Influence: 0.4] [Reference Citation Analysis]
278 Tamura T, Kuwahara A, Yamamori M, Nishiguchi K, Nakamura T, Okuno T, Miki I, Manabe Y, Sakaeda T. VEGF -634C/G genotype is predictive of long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. Int J Med Sci 2012;9:833-7. [PMID: 23155356 DOI: 10.7150/ijms.4914] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
279 McNamara MJ, Adelstein DJ. Current developments in the management of locally advanced esophageal cancer. Curr Oncol Rep. 2012;14:342-349. [PMID: 22544559 DOI: 10.1007/s11912-012-0239-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
280 Lordick F, Hölscher AH, Haustermans K, Wittekind C. Multimodal treatment of esophageal cancer. Langenbecks Arch Surg 2013;398:177-87. [PMID: 22971784 DOI: 10.1007/s00423-012-1001-1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
281 Taketa T, Correa AM, Suzuki A, Blum MA, Chien P, Lee JH, Welsh J, Lin SH, Maru DM, Erasmus JJ, Bhutani MS, Weston B, Rice DC, Vaporciyan AA, Hofstetter WL, Swisher SG, Ajani JA. Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation. Oncology 2012;83:300-4. [PMID: 22964903 DOI: 10.1159/000341353] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
282 Jabbour SK, Thomas CR Jr. Radiation therapy in the postoperative management of esophageal cancer. J Gastrointest Oncol 2010;1:102-11. [PMID: 22811814 DOI: 10.3978/j.issn.2078-6891.2010.013] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
283 Hayashi Y, Xiao L, Suzuki A, Blum MA, Sabloff B, Taketa T, Maru DM, Welsh J, Lin SH, Weston B, Lee JH, Bhutani MS, Hofstetter WL, Swisher SG, Ajani JA. A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer. Eur J Cancer 2012;48:3396-404. [PMID: 22853875 DOI: 10.1016/j.ejca.2012.06.020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
284 Rahma OE, Greten TF, Duffy A. Locally advanced cancer of the esophagus, current treatment strategies, and future directions. Front Oncol 2012;2:52. [PMID: 22655277 DOI: 10.3389/fonc.2012.00052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
285 Wolf MC, Zehentmayr F, Schmidt M, Hölzel D, Belka C. Treatment strategies for oesophageal cancer - time-trends and long term outcome data from a large tertiary referral centre. Radiat Oncol 2012;7:60. [PMID: 22501022 DOI: 10.1186/1748-717X-7-60] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
286 Thakur B, Zhang CS, Guo Y, Lama R. Comparison Between Concurrent Chemoradiation Followed by Surgery vs. Surgery for Locally Advanced Cancer of Esophagus. Indian J Surg 2011;73:111-5. [PMID: 22468059 DOI: 10.1007/s12262-010-0182-5] [Reference Citation Analysis]
287 Blanchard P, Quero L, Pacault V, Schlageter MH, Baruch-Hennequin V, Hennequin C. Prognostic significance of anti-p53 and anti-KRas circulating antibodies in esophageal cancer patients treated with chemoradiotherapy. BMC Cancer. 2012;12:119. [PMID: 22448886 DOI: 10.1186/1471-2407-12-119] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
288 Jarral OA, Purkayastha S, Athanasiou T, Darzi A, Hanna GB, Zacharakis E. Thoracoscopic esophagectomy in the prone position. Surg Endosc. 2012;26:2095-2103. [PMID: 22395952 DOI: 10.1007/s00464-012-2172-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
289 Habermehl D, Kessel K, Welzel T, Hof H, Abdollahi A, Bergmann F, Rieken S, Weitz J, Werner J, Schirmacher P. Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer. Radiat Oncol. 2012;7:28. [PMID: 22385572 DOI: 10.1186/1748-717x-7-28] [Cited by in Crossref: 67] [Cited by in F6Publishing: 58] [Article Influence: 6.7] [Reference Citation Analysis]
290 Fakhrian K, Gamisch N, Schuster T, Thamm R, Molls M, Geinitz H. Salvage radiotherapy in patients with recurrent esophageal carcinoma. Strahlenther Onkol. 2012;188:136-142. [PMID: 22218502 DOI: 10.1007/s00066-011-0023-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
291 Goodman KA. Radiation in rectal cancer: what are the options and if/when can it be avoided? Am Soc Clin Oncol Educ Book 2012;:219-21. [PMID: 24451738 DOI: 10.14694/EdBook_AM.2012.32.91] [Reference Citation Analysis]
292 Hermida Pérez J, Bermejo Hernández A, Sobenes Gutierrez R, Arroyo Díaz R. Carcinoma epidermoide de esófago, estenosante, estadio IV, en mujer de 41 años. Descripción de un caso clínico. SEMERGEN - Medicina de Familia 2012;38:44-8. [DOI: 10.1016/j.semerg.2011.06.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
293 Mcglone ER, Khan OA. Prognostic benefit of surgery following chemoradiotherapy for squamous cell carcinoma of the oesophagus. International Journal of Surgery 2012;10:341-4. [DOI: 10.1016/j.ijsu.2012.05.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
294 Pan JY, Ajani JA, Gu J, Gong Y, Qin A, Hung M, Wu X, Izzo JG. Association of Aurora-A (STK15) kinase polymorphisms with clinical outcome of esophageal cancer treated with preoperative chemoradiation. Cancer 2012;118:4346-53. [PMID: 22213102 DOI: 10.1002/cncr.26581] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
295 Matuschek C, Bölke E, Zahra T, Knoefel WT, Peiper M, Budach W, Erhardt A, Scherer A, Baldus SE, Gerber PA, Buhren BA, Schauer M, Hoff NP, Gattermann N, Orth K. Trimodal therapy in squamous cell carcinoma of the esophagus. Eur J Med Res 2011;16:437-44. [PMID: 22024422 DOI: 10.1186/2047-783x-16-10-437] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
296 Power DG, Ilson DH. Integration of targeted agents in the neo-adjuvant treatment of gastro-esophageal cancers. Ther Adv Med Oncol 2009;1:145-65. [PMID: 21789119 DOI: 10.1177/1758834009347323] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
297 Ott K, Sisic L, Büchler M. [Squamous cell carcinoma of the esophagus]. Chirurg 2011;82:974-80. [PMID: 22002703 DOI: 10.1007/s00104-011-2128-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
298 Low DE. Update on staging and surgical treatment options for esophageal cancer. J Gastrointest Surg 2011;15:719-29. [PMID: 21487832 DOI: 10.1007/s11605-011-1515-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
299 Matuschek C, Bölke E, Peiper M, Knoefel WT, Budach W, Erhardt A, Scherer A, Gerber PA, Buhren BA, Gattermann N, Baldus SE, Rusnak E, Shukla V, Orth K. The role of neoadjuvant and adjuvant treatment for adenocarcinoma of the upper gastrointestinal tract. Eur J Med Res 2011;16:265-74. [PMID: 21810561 DOI: 10.1186/2047-783x-16-6-265] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
300 Bystricky B, Okines AF, Cunningham D. Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer. Drugs. 2011;71:541-555. [PMID: 21443280 DOI: 10.2165/11585460-000000000-000003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
301 Bystricky B, Okines AF, Cunningham D. Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer. Drugs 2011;71:541-55. [PMID: 21443280 DOI: 10.2165/11585460-000000000-00000] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
302 Palmes D, Brüwer M, Bader FG, Betzler M, Becker H, Bruch HP, Büchler M, Buhr H, Ghadimi BM, Hopt UT, Konopke R, Ott K, Post S, Ritz JP, Ronellenfitsch U, Saeger HD, Senninger N; German Advanced Surgical Treatment Study Group. Diagnostic evaluation, surgical technique, and perioperative management after esophagectomy: consensus statement of the German Advanced Surgical Treatment Study Group. Langenbecks Arch Surg 2011;396:857-66. [PMID: 21713594 DOI: 10.1007/s00423-011-0818-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
303 Wolf MC, Stahl M, Krause BJ, Bonavina L, Bruns C, Belka C, Zehentmayr F. Curative treatment of oesophageal carcinoma: current options and future developments. Radiat Oncol. 2011;6:55. [PMID: 21615894 DOI: 10.1186/1748-717x-6-55] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
304 Swisher SG, Winter KA, Komaki RU, Ajani JA, Wu TT, Hofstetter WL, Konski AA, Willett CG. A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246. Int J Radiat Oncol Biol Phys 2012;82:1967-72. [PMID: 21507583 DOI: 10.1016/j.ijrobp.2011.01.043] [Cited by in Crossref: 52] [Cited by in F6Publishing: 43] [Article Influence: 4.7] [Reference Citation Analysis]
305 Yoon MS, Nam TK, Lee JS, Cho SH, Song JY, Ahn SJ, Chung IJ, Jeong JU, Chung WK, Nah BS. VEGF as a predictor for response to definitive chemoradiotherapy and COX-2 as a prognosticator for survival in esophageal squamous cell carcinoma. J Korean Med Sci. 2011;26:513-520. [PMID: 21468258 DOI: 10.3346/jkms.2011.26.4.513] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
306 Bedenne L, Vincent J, Jouve J. Is surgery always necessary in esophageal cancer? Esophagus 2011;8:3-7. [DOI: 10.1007/s10388-011-0258-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
307 Triboulet JP. [Salvage surgery: cancer of the esophagus]. Bull Cancer 2011;98:73-8. [PMID: 21300611 DOI: 10.1684/bdc.2010.1293] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
308 Monjazeb AM, Riedlinger G, Aklilu M, Geisinger KR, Mishra G, Isom S, Clark P, Levine EA, Blackstock AW. Outcomes of patients with esophageal cancer staged with [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection? J Clin Oncol 2010;28:4714-21. [PMID: 20876421 DOI: 10.1200/JCO.2010.30.7702] [Cited by in Crossref: 92] [Cited by in F6Publishing: 84] [Article Influence: 7.7] [Reference Citation Analysis]
309 Tougeron D, Hamidou H, Scotté M, Di Fiore F, Antonietti M, Paillot B, Michel P. Esophageal cancer in the elderly: an analysis of the factors associated with treatment decisions and outcomes. BMC Cancer. 2010;10:510. [PMID: 20868479 DOI: 10.1186/1471-2407-10-510] [Cited by in Crossref: 23] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
310 Choong NW, Mauer AM, Haraf DC, Ferguson MK, Sandler AB, Kesler KA, Fishkin PA, Ansari RH, Wade J 3rd, Krauss SA, Sciortino DF, Posner MC, Kocherginsky M, Hoffman PC, Szeto L, Vokes EE. Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction. Med Oncol 2011;28 Suppl 1:S152-61. [PMID: 20730572 DOI: 10.1007/s12032-010-9658-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
311 Barreto JC, Posner MC. Transhiatal versus transthoracic esophagectomy for esophageal cancer. World J Gastroenterol 2010; 16(30): 3804-3810 [PMID: 20698043 DOI: 10.3748/wjg.v16.i30.3804] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 54] [Article Influence: 4.9] [Reference Citation Analysis]
312 Twine CP, Roberts SA, Lewis WG, Dave BV, Rawlinson CE, Chan D, Robinson M, Crosby TD. Prognostic significance of endoluminal ultrasound-defined disease length and tumor volume (EDTV) for patients with the diagnosis of esophageal cancer. Surg Endosc 2010;24:870-8. [PMID: 19730945 DOI: 10.1007/s00464-009-0681-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
313 Greenwald BD, Dumot JA, Abrams JA, Lightdale CJ, David DS, Nishioka NS, Yachimski P, Johnston MH, Shaheen NJ, Zfass AM, Smith JO, Gill KR, Burdick JS, Mallat D, Wolfsen HC. Endoscopic spray cryotherapy for esophageal cancer: safety and efficacy. Gastrointest Endosc. 2010;71:686-693. [PMID: 20363410 DOI: 10.1016/j.gie.2010.01.042] [Cited by in Crossref: 91] [Cited by in F6Publishing: 78] [Article Influence: 7.6] [Reference Citation Analysis]
314 Takeuchi H, Saikawa Y, Oyama T, Ozawa S, Suda K, Wada N, Takahashi T, Nakamura R, Shigematsu N, Ando N, Kitajima M, Kitagawa Y. Factors influencing the long-term survival in patients with esophageal cancer who underwent esophagectomy after chemoradiotherapy. World J Surg 2010;34:277-84. [PMID: 20033687 DOI: 10.1007/s00268-009-0331-9] [Cited by in Crossref: 59] [Cited by in F6Publishing: 61] [Article Influence: 4.9] [Reference Citation Analysis]
315 Forastiere AA. Multimodality treatment of esophagus cancer: current status and future perspectives in the United States. Esophagus 2010;7:1-6. [DOI: 10.1007/s10388-009-0226-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
316 Bain GH, Petty RD. Predicting response to treatment in gastroesophageal junction adenocarcinomas: combining clinical, imaging, and molecular biomarkers. Oncologist 2010;15:270-84. [PMID: 20203174 DOI: 10.1634/theoncologist.2009-0293] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
317 Kranzfelder M, Büchler P, Friess H. Surgery within multimodal therapy concepts for esophageal squamous cell carcinoma (ESCC): the MRI approach and review of the literature. Adv Med Sci 2009;54:158-69. [PMID: 20022858 DOI: 10.2478/v10039-009-0044-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
318 Pühringer-Oppermann F, Sarbia M, Ott N, Brücher BL. The predictive value of genes of the TGF-beta1 pathway in multimodally treated squamous cell carcinoma of the esophagus. Int J Colorectal Dis 2010;25:515-21. [PMID: 20012971 DOI: 10.1007/s00384-009-0867-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
319 Abrams JA, Buono DL, Strauss J, McBride RB, Hershman DL, Neugut AI. Esophagectomy compared with chemoradiation for early stage esophageal cancer in the elderly. Cancer. 2009;115:4924-4933. [PMID: 19637343 DOI: 10.1002/cncr.24536] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 3.8] [Reference Citation Analysis]
320 Cheng S, Iannettoni M, Koshy M, Suntharalingam M, Urba S. Squamous cell carcinoma of the esophagus: treat with how many modalities? Semin Oncol 2009;36:493-7. [PMID: 19995639 DOI: 10.1053/j.seminoncol.2009.09.002] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
321 Crosby T, Evans M, Gillies RS, Maynard ND. The management of a patient with an operable carcinoma of the oesophagus. Ann R Coll Surg Engl 2009;91:366-70. [PMID: 19622256 DOI: 10.1308/003588409X432428] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
322 Tinkl D, Grabenbauer GG, Golcher H, Meyer T, Papadopoulos T, Hohenberger W, Sauer R, Brunner TB. Downstaging of pancreatic carcinoma after neoadjuvant chemoradiation. Strahlenther Onkol. 2009;185:557-566. [PMID: 19756421 DOI: 10.1007/s00066-009-1977-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
323 Stahl M. [Combined preoperative radiochemotherapy in squamous cell carcinoma. The view of the medical oncologist]. Chirurg 2009;80:1006-10. [PMID: 19730797 DOI: 10.1007/s00104-009-1732-x] [Reference Citation Analysis]
324 Jensen AD, Grehn C, Nikoghosyan A, Thieke C, Krempien R, Huber PE, Debus J, Münter MW. Catch me if you can--the use of image guidance in the radiotherapy of an unusual case of esophageal cancer. Strahlenther Onkol. 2009;185:469-473. [PMID: 19714309 DOI: 10.1007/s00066-009-1935-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
325 Goldfarb M, Brower S, Schwaitzberg SD. Minimally invasive surgery and cancer: controversies part 1. Surg Endosc. 2010;24:304-334. [PMID: 19572178 DOI: 10.1007/s00464-009-0583-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
326 Conroy T. [Clinical case: should esophageal cancers still be operated on?]. Gastroenterol Clin Biol 2009;33:285-8. [PMID: 19304427 DOI: 10.1016/j.gcb.2009.02.013] [Reference Citation Analysis]
327 Javle M, Hsueh CT. Updates in Gastrointestinal Oncology - insights from the 2008 44th annual meeting of the American Society of Clinical Oncology. J Hematol Oncol 2009;2:9. [PMID: 19236713 DOI: 10.1186/1756-8722-2-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
328 Tachimori Y. Role of salvage esophagectomy after definitive chemoradiotherapy. Gen Thorac Cardiovasc Surg 2009;57:71-8. [PMID: 19214447 DOI: 10.1007/s11748-008-0337-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
329 Ribi K, Koeberle D, Schuller JC, Honegger H, Roth A, Hess V, Moosmann P, von Moos R, Borner M, Lombriser N. Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation? Support Care Cancer. 2009;Feb 7; Epub ahead of print. [PMID: 19198893 DOI: 10.1007/s00520-008-0570-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
330 Zingg U, Divalentino D, McQuinn A, Mardzuki A, Thompson SK, Karapetis CS, Watson DI. Outcome for esophageal cancer following treatment with chemotherapy and radiotherapy but not esophagectomy: Nonsurgical treatment of esophageal cancer. Clin Exp Gastroenterol 2009;2:75-83. [PMID: 21694830 DOI: 10.2147/ceg.s6273] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
331 Matsubara H. Neoadjuvant chemoradiation therapy for the treatment of esophageal carcinoma. Int J Clin Oncol 2008;13:474-8. [PMID: 19093172 DOI: 10.1007/s10147-008-0853-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
332 Teyton P, Metges JP, Atmani A, Jestin-Le Tallec V, Volant A, Visvikis D, Bail JP, Pradier O, Lozac'h P, Cheze Le Rest C. Use of positron emission tomography in surgery follow-up of esophageal cancer. J Gastrointest Surg. 2009;13:451-458. [PMID: 19023632 DOI: 10.1007/s11605-008-0749-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
333 Tougeron D, Di Fiore F, Thureau S, Berbera N, Iwanicki-Caron I, Hamidou H, Paillot B, Michel P. Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer. Br J Cancer 2008;99:1586-92. [PMID: 19002180 DOI: 10.1038/sj.bjc.6604749] [Cited by in Crossref: 71] [Cited by in F6Publishing: 82] [Article Influence: 5.1] [Reference Citation Analysis]
334 Lorenzen S, Brücher B, Zimmermann F, Geinitz H, Riera J, Schuster T, Roethling N, Höfler H, Ott K, Peschel C, Siewert JR, Molls M, Lordick F. Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial. Br J Cancer 2008;99:1020-6. [PMID: 18797462 DOI: 10.1038/sj.bjc.6604659] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
335 Gines A, Cassivi SD, Martenson JA Jr, Schleck C, Deschamps C, Sinicrope FA, Alberts SR, Murray JA, Zinsmeister AR, Vazquez-Sequeiros E, Nichols FC 3rd, Miller RC, Quevedo JF, Allen MS, Alexander JA, Zais T, Haddock MG, Romero Y. Impact of endoscopic ultrasonography and physician specialty on the management of patients with esophagus cancer. Dis Esophagus 2008;21:241-50. [PMID: 18430106 DOI: 10.1111/j.1442-2050.2007.00766.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
336 Cronin-Fenton DP, Mooney MM, Clegg LX, Harlan LC. Treatment and survival in a population-based sample of patients diagnosed with gastroesophageal adenocarcinoma. World J Gastroenterol 2008; 14(20): 3165-3173 [PMID: 18506920 DOI: 10.3748/wjg.14.3165] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
337 Saito Y, Andoh A, Hata K, Tsujikawa T, Ogawa A, Nakahara T, Kushima R, Fujiyama Y. Chemoradiation therapy followed by endoscopic submucosal dissection for esophageal cancer. Dig Dis Sci 2008;53:3242-5. [PMID: 18470613 DOI: 10.1007/s10620-008-0291-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
338 Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008;26:1086-92. [PMID: 18309943 DOI: 10.1200/JCO.2007.12.9593] [Cited by in Crossref: 860] [Cited by in F6Publishing: 856] [Article Influence: 61.4] [Reference Citation Analysis]
339 Gómez Senent S, Gómez Raposo C, Segura Cabral JM. Cáncer de esófago. Medicina Clínica 2008;130:423-8. [DOI: 10.1157/13117853] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
340 Jackson C, Starling N, Chua YJ, Cunningham D. Pharmacotherapy for oesophagogastric cancer. Drugs 2007;67:2539-56. [PMID: 18034590 DOI: 10.2165/00003495-200767170-00006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
341 Di Fiore F, Lecleire S, Pop D, Rigal O, Hamidou H, Paillot B, Ducrotté P, Lerebours E, Michel P. Baseline nutritional status is predictive of response to treatment and survival in patients treated by definitive chemoradiotherapy for a locally advanced esophageal cancer. Am J Gastroenterol 2007;102:2557-63. [PMID: 17680847 DOI: 10.1111/j.1572-0241.2007.01437.x] [Cited by in Crossref: 116] [Cited by in F6Publishing: 118] [Article Influence: 7.7] [Reference Citation Analysis]
342 Low DE, Kunz S, Schembre D, Otero H, Malpass T, Hsi A, Song G, Hinke R, Kozarek RA. Esophagectomy--it's not just about mortality anymore: standardized perioperative clinical pathways improve outcomes in patients with esophageal cancer. J Gastrointest Surg 2007;11:1395-402; discussion 1402. [PMID: 17763917 DOI: 10.1007/s11605-007-0265-1] [Cited by in Crossref: 135] [Cited by in F6Publishing: 117] [Article Influence: 9.0] [Reference Citation Analysis]
343 Doki Y, Yasuda T, Miyata H, Fujiwara Y, Takiguchi S, Yamasaki M, Makari Y, Matsuyama J, Masuoka T, Monden M. Salvage lymphadenectomy of the right recurrent nerve node with tracheal involvement after definitive chemoradiation therapy for esophageal squamous cell carcinoma: report of two cases. Surg Today 2007;37:590-5. [PMID: 17593480 DOI: 10.1007/s00595-006-3447-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
344 Konski AA, Cheng JD, Goldberg M, Li T, Maurer A, Yu JQ, Haluszka O, Scott W, Meropol NJ, Cohen SJ, Freedman G, Weiner LM. Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma. Int J Radiat Oncol Biol Phys 2007;69:358-63. [PMID: 17532577 DOI: 10.1016/j.ijrobp.2007.03.053] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 2.7] [Reference Citation Analysis]
345 Gemici C. The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma. Cancer 2007;109:1448-9; author reply 1449. [PMID: 17328063 DOI: 10.1002/cncr.22514] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
346 Hölscher AH, Schneider PM, Gutschow C, Schröder W. Laparoscopic ischemic conditioning of the stomach for esophageal replacement. Ann Surg 2007;245:241-6. [PMID: 17245177 DOI: 10.1097/01.sla.0000245847.40779.10] [Cited by in Crossref: 157] [Cited by in F6Publishing: 143] [Article Influence: 10.5] [Reference Citation Analysis]
347 Michel P, Adenis A, Di Fiore F, Boucher E, Galais MP, Dahan L, Mirabel X, Hamidou H, Raoul JL, Jacob JH. Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial. Br J Cancer. 2006;95:705-709. [PMID: 16967056 DOI: 10.1038/sj.bjc.6603328] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 2.3] [Reference Citation Analysis]
348 Hyodo I. Promise of definitive chemoradiotherapy for esophageal cancer balanced with late radiation toxicity: an old but new issue. J Gastroenterol 2006;41:504-6. [PMID: 16799897 DOI: 10.1007/s00535-006-1835-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
349 Dawson SJ, Michael M, Biagi J, Foo KF, Jefford M, Ngan SY, Leong T, Hui A, Milner AD, Thomas RJ. A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer. Invest New Drugs. 2007;25:123-129. [PMID: 17053988 DOI: 10.1007/s10637-006-9016-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 1.4] [Reference Citation Analysis]
350 Delgado Gomis F, Gómez Abril SA, Martínez Abad M, Guallar Rovira JM. Assisted laparoscopic transhiatal esophagectomy for the treatment of esophageal cancer. Clin Transl Oncol 2006;8:185-92. [PMID: 16648118 DOI: 10.1007/s12094-006-0009-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
351 Fiore FD, Lecleire S, Rigal O, Galais MP, Soussan EB, David I, Paillot B, Jacob JH, Michel P. Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma. World J Gastroenterol 2006; 12(26): 4185-4190 [PMID: 16830371 DOI: 10.3748/wjg.v12.i26.4185] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 50] [Article Influence: 3.0] [Reference Citation Analysis]
352 Levine EA, Farmer MR, Clark P, Mishra G, Ho C, Geisinger KR, Melin SA, Lovato J, Oaks T, Blackstock AW. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg. 2006;243:472-478. [PMID: 16552197 DOI: 10.1097/01.sla.0000208430.07050.61] [Cited by in Crossref: 124] [Cited by in F6Publishing: 113] [Article Influence: 7.8] [Reference Citation Analysis]
353 Sarbia M, Stahl M, von Weyhern C, Weirich G, Pühringer-Oppermann F. The prognostic significance of genetic polymorphisms (Methylenetetrahydrofolate Reductase C677T, Methionine Synthase A2756G, Thymidilate Synthase tandem repeat polymorphism) in multimodally treated oesophageal squamous cell carcinoma. Br J Cancer 2006;94:203-7. [PMID: 16333305 DOI: 10.1038/sj.bjc.6602900] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.2] [Reference Citation Analysis]
354 Schneider PM, Vallböhmer D, Brabender J, Hölscher AH. [Preoperative evaluation of prognostic factors in esophageal squamous cell cancer]. Chirurg 2005;76:1011-7. [PMID: 16247636 DOI: 10.1007/s00104-005-1109-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]